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缺 本 研 究 將 手 作 的 尿 檸 檬 酸 鹽 定 量 法 自 動 化 ， 應 用 于 C o b a s Fara H 
離 心 分 析 儀 . 此 定 量 法 採 用 檸 檬 酸 裂 解 腾 分 解 檸 檬 酸 鹽 成 草 先 乙 酸 
及 乙 酸 鹽 . 草 | 统 乙 酸 與 苯 拼 于 輕 微 酸 度 下 結 合 成 苯 3 宗 . 苯 g 宗 強 烈 
J ? ^ ? } 3 3 0 膽 之 紫 外 線 . 分 光 光 度 計 測 量 出 的 苯 s 宗 濃 度 與 擰 i 
敬盥淚度成正比. 
此 定 量 法 自 0 至 4 mmol/L檸檬酸鹽保持線形關係 .測量低限為 
0 0 5 平 均 批 内 變 异 1 . 4 % ， 批 間 變 异 3 . 0 % ， 平 均 回 收 率 
1 0 1 . 3 % . 内 源 丙 酮 酸 鹽 及 草 耽 乙 酸 若 低 于 2 皿 ‘ ， 均 不 顯 著 干 擾 
亡 i f ? . 比 較 手 作 的 定 量 法 ， 自 動 化 的 測 定 較 精 確 , 靈 敏 及 快 速 ， 值 
付推廣為泌尿道結石患者探測低尿擰檬酸鹽 . 
^ ^ t f 究 為 香 港 首 個 分 析 中 國 泌 尿 道 結 石 病 人 尿 檸 檬 酸 鹽 之 臨 床 
貫驗 .48例病患者的尿檸檬酸鹽排出量比正常同性對照組顯著減少 
( 男 ： 1 ^ < 0 0 0 0 1 ; 女 ： p < 0 . 0 2 ) . 當 中 1 6 例 為 低 尿 擰 檬 酸 蔑 ' ( : 3 6 1 
= ， ) ’ 彳 ^ 了 3 3 % 泌 尿 道 結 石 病 人 . 此 外 ， 該 4 8 例 病 患 者 的 尿 鎂 
巧 J i 正 常 對 照 組 顯 著 減 少 ^ 0 . 0 5 ^ 低 尿 擰 檬 酸 璺 與 低 尿 鎮 皆 為 、 泌尿道結石形成的素因. 曰门 
總而言之，在中國人口低尿擰檬酸鹽是泌尿道結石形成的普遍 




An enzyme-spectrophotometric method for the quantitation of urinary citrate was 
adapted to the Cobas Fara centrifugal analyzer. This automated assay employed a 
specific enzyme citrate lyase to cleave citrate into oxaloacetate and acetate. The 
oxaloacetate reacted rapidly with phenylhydrazine at slightly acidic pH to form 
oxaloacetate-phenylhydrazone. This end product exhibited strong UV-absorbing 
property and was monitored at 330 nm. 
The automated assay was linear over a wide range of citrate concentrations (0 to 
4 mmol/L) and had a low detection limit of 0.05 mmol/L. The imprecision, recovery 
and carryover were within acceptable limits. Both endogenous pyruvate and 
oxaloacetate up to 2 mmol/L did not interfere significantly with the assay. This assay 
was well correlated with the traditional citrate lyase method. The running time was 
within 15 minutes. It was a satisfactory method for detecting hypocitraturia. 
In the first clinical study in Hong Kong on forty-eight Chinese patients with 
nephrolithiasis, it was discovered that they excreted remarkably less citrate compared 
to sex-matched normal subjects. Sixteen patients were hypocitraturic (cut-off value : 
0.65 mmol/day), accounting for a significant proportion (33%) of the stone formers. 
Apart from a decreased urinary citrate excretion, the stone patients excreted 
significantly less magnesium than the controls. Reduced excretion of the two stone 
inhibitors predisposed to nephrolithiasis. 
In conclusion, hypocitraturia is a common predisposition factor in Chinese 
patients with nephrolithiasis. Oral citrate therapy should be considered to reduce 
recurrence of nephrolithiasis in the stone patients. The automated citrate-lyase 
• 窄 . . . : n --
phenylhydrazine assay for urinary citrate is useful to diagnose hypocitraturia and 
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SUMMARY 
An enzyme-spectrophotometric method for the quantitation ofurinaiy citrate was 
adapted to the Cobas Fara centrifugal analyzer. This automated assay employed a 
specific enzyme citrate lyase to cleave citrate into oxaloacetate and acetate. The 
oxaloacetate reacted rapidly with phenylhydrazine at slightly acidic pH to form 
oxaloacetate-phenylhydrazone. This end product exhibited strong UV-absorbing 
property and was monitored at 330 nm. 
The automated assay was linear over a wide range of citrate concentrations (0 to 
4 mmoI/L) and had a low detection limit of 0.05 mmol/L. The imprecision, recovery 
and carryover were within acceptable limits. Both endogenous pyruvate and 
oxaloacetate up to 2 mmol/L did not interfere significantly with the assay. This assay 
was well correlated with the traditional citrate lyase method. The running time was 
within 15 minutes. It was a satisfactory method for detecting hypocitraturia 
In the first clinical study in Hong Kong on forty-eight Chinese patients with 
nephrolithiasis, it was discovered that they excreted remarkably less citrate compared to 
sex-matched normal subjects. Sixteen patients were hypocitraturic (cut-off value : 0.65 
mmol/day), accounting for a significant proportion (33%) of the stone formers. Apart 
from a decreased urinary citrate excretion, the stone patients excreted significantly less 
magnesium than the controls. Reduced excretion of the two stone inhibitors 
predisposed to nephrolithiasis. 
In conclusion, hypocitraturia is a common predisposition factor in Chinese 
patients with nephrolithiasis. Oral citrate therapy should be considered to reduce 
recurrence of nephrolithiasis in the stone patients. The automated citrate-lyase 
viii 
phenylhydrazine assay for urinary citrate is useful to diagnose hypocitraturia and 
monitor the patients on citrate therapy. 
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U Introduction 
Nephrolithiasis is a common disorder. It refers to the clinical condition that 
calculi form in the renal calyces and pelvis. Its incidence rate is about 0.2% of the 
population of the United States per year[ 1 ]. Between 5 and 15% of Americans will 
suffer from renal calculi sometime during their lifetimef 1 ]. Nephrolithiasis is also 
common in the Chinese population, with an incidence rate of 0.17% of the 
population of Hong Kong in 1995 [2]. 
Nephrolithiasis, if untreated, would cause obstructive uropathy and renal 
failure. Furthermore, recurrence rates are high: 50% of the patients will have 
another stone within 5 years[ 1 ]. In the United States, nephrolithiasis accounted for 
0.9% of hospital discharges, costing 1.83 billion dollars of medical expenses in 1993 
[ 3 ]. An understanding of the mechanism of nephrolithiasis helps to improve the 
patient management. The morbidity and health care costs associated with 
nephrolithiasis would thus be reduced. 
Renal stones are composed of inorganic or organic substances with 
crystalline or amorphous structure (table 1). Calcium oxalate is by far the most 
common stone component[ 1 ]. About 70 to 75% of renal stones in Western 
population are composed of calcium oxalate[ 4 ]. Most calcium oxalate stones also 
contain a small amount of calcium phosphate. Calcium oxalate and calcium 
phosphate stones are black, gray or white in color. They appear as small (less than 1 
cm in diameter), dense, opaque and sharply circumscribed shadow on x-ray films. 
Another 10% of renal stones are struvite (magnesium ammonium phosphate) 
based[ 5 ]. A further 10% are uric acid based. Cystine and xanthine stones make up 
less than 1%. 
1 
Composition % total Cause(s) . 
Calcium oxalate 70-80 1. Primary hyperparathyroidism 




Calcium phosphate 5-10 Renal tubular acidosis 
Struvite (magnesium 5-10 Urinary tract infection with urease-
ammonium calcium producing bacteria 
phosphate) 
Uric acid 5-10 1. Low urine pH 
2. Hypemricosuria 
Cystine 1-5 Cystinuria ; 
Table 1: Chemical composition and causes of renal stones 
(modified from Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of 
kidney stones. The New England Journal of Medicine 1992;327,16,1141-1152) 
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Nephrolithiasis is a complex physico-chemical process, depending on the 
balance between supersaturation of the constituents of renal stone and their 
inhibitors in urine[ 3 ]• Supersaturation describes the condition that urine cantains 
more stone constituents than it can hold when it is saturated with them. When the 
solubility product of the stone components is exceeded, they tend to precipitate out, 
and crystals first appear in urine. They must grow or aggregate into large clumps, 
adhere and deposit themselves onto renal tubular cells before a renal stone is 
developed[ 3 ]. On the other hand, normal urine contains inorganic and organic 
inhibitors. They act agmnst the crystallization potential of urine in the presence of 
high concentration of stone constituents in normal urine[ 3 
Many studies have been conducted to investigate the mechanism of renal 
stone formation and its prevention in Western patients with nephrolithiasis. 
Important metabolic disturbances favouring nephrolithiasis include idiopathic 
hypercalciuria，renal tubular acidosis, hyperparathyroidism, primary hyperoxaluria, 
hyperuricosuria, cystinuria, xanthinuria (table 1). Other non-metabolic precipitants 
are dietary habit, dehydration, urinary tract infection, and renal anatomical 
predisposition to stones[ 1 ]. 
Much interests have also been focused on the inhibitors of renal stone 
formation and recurrence. Essential inhibitors comprise urinary citrate, magnesium, 
glycosaminoglycans (GAGs), pyrophosphate, uropontin, Tamm-Horsfall protein 
and nephrocalcinf 3 ]• Studies have revealed that 15 to 63% of Western patients 
with nephrolithiasis are associated with hypocitraturia (daily urinary citrate 
excretion less than 1.7 mmol) [ 3 ]. Hypocitraturia may be the single cause of renal 
stones in 5 to 10% of the stone patients[ 1 ]• Another study has shown that 
3 
hypocitraturia is found in 45% of Chinese patients with nephrolithiasis in 
Taiwan[ 6 ]. Their urinary citrate excretion is below 0.65 mmol/day. The use of 
potassium citrate or bicarbonate to promote urinary citrate excretion has been 
recommended in Western patients with nephrolithiasis[ 7 ]. 
To my knowledge, there are only a few comprehensive study of urinary citrate 
excretion in the Chinese population and stone-formers. This will be the first study 
on urinary citrate in Hong Kong. The aim of this project is to evaluate and compare 
the urinary citrate excretion in normal Chinese subjects and in Chinese patients with 
nephrolithiasis. An automated enzyme-spectrophotometric method is adapted for 
the quantitation of urinary citrate. Urinary citrate is studied together with other 
parameters like 24-hour urinary excretion of calcium, phosphate, oxalate and 
magnesium in these patients. 
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2. Brief Review on Nephrolithiasis 
2.1 Mechanism of nephrolithiasis 
The process leading to nephrolithiasis is multifactorial in origin[ 8 ]• Metabolic 
abnormalities may act in concert with genetic, racial, geographic, socio-economic, 
dietary, pharmacologic, as well as urinary tract functional and structural factors to 
potentiate the physico-chemical change in the stone formation process (table 2). 
The physico-chemical mechanism of nephrolithiasis is briefly described as follows 
丨 [3]： 
2.1.1 Saturation 
Saturation of the stone components is the most important factor in the initiation 
of crystallization in urine. Saturation depends on the solubilities of stone components, 
which are determined by their concentrations, the urine pH and other urine constituents. 
The concentrations of the components at which saturation occurs and 
crystallization begins are related mathematically by the solubility product (Ksp). This is 
the mathematical product of the concentrations of the pure solute components at 
saturation. 
Variations of urine pH can affect the solubility of stone components. Increasing 
urine pH favours the ionization of phosphates, thus making calcium phosphate less 
soluble in urine. On the other hand, uric acid will become at least twenty-five times 
more soluble if the urine pH is changed from 5 to 7. Urine alkalisation has been applied 
to treat patients with uric acid stones[ 9 ]. 
5 
Race Geographic Sex, Age & Inheritance Socio-economic 
location Nutrition condition 
卜 . . . ... 
Metabolic Renal Disturbed urine Urinary tract Genetic 
disturbances anatomic flow&pH infection factors 
abnormalities 
Increased urinary excretion of Reduced urinary excretion of inhibitors of 
constituents of renal stone renai stone formation 
Physico-chemical change in the urinary 
supersaturation state 
I : ‘ 




Table 2: Factors contributing to nephrolithiasis 
(Modified from Hesse A, Tiselius HG, Jahnen A (eds). Urinary Stones: Diagnosis， 
Treatment and Prevention of Recurrence (in Introduction). Karger, Jul 1996:15) 
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2.1.2 Supersaturation 
Supersaturation occurs when the urine contains more stone constituents than it 
can hold when it is saturated with them. It occurs when the urinary excretion of the 
stone constituents increases, when the urine volume decreases, and when the 
concentrations of the urinary inhibitors of nephrolithiasis are reduced. It is a 
prerequisite for starting precipitation of the stone components to form ciystals 
(nucleation) when the solubility product is exceeded. However, urine is a complex 
solution containing many other ions interacting with calcium and phosphate. Citrate and 
magnesium in urine will modify crystallization, allowing a higher concentration of 
calcium phosphate to be held in urine than in pure solvents. 
2.1.3 Heterogeneous nucleation 
This process describes the formation of the earliest insoluble crystal nuclei with a 
characteristic lattice pattern on the surfaces of red cells, epithelial cells, casts, or other 
crystals such as uric acid which act as nucleating foci in urine. 
2.1.4 Crystal growth or aggregation 
The crystal nuclei aggregates by chemical or electrical forces. However, new 
crystals will not be formed unless the supersaturation has to exceed a threshold defined 
by the formation product (Kf) of the stone components. Kf is the concentration at 
which the urine can hold no more stone constituents. It is always greater than Ksp. 
2.1.5 Crystal retention 
Free crystals formed within the renal tubules are probably incapable of growing 
large enough to form a stone and occlude papillary or collecting ducts in the absence of 
urinary stagnation. Renal structural abnormalities (for instance medullary sponge 
7 
kidney) and functional defects facilitate crystal retention, allowing further ciystal 
growth and deposition for longer periods. This is crucial for the transformation of 
fragile crystals into stone, especially for calcium oxalate stones. Altered tubular 
function involving increased solute transport into the cells or interstitial spaces 
aggravates crystal deposition[10]. E. coH causing urinary tract infection may provoke 
calcium oxalate stone formation by producing matrix substances which in turn augment 
crystal fixation to tubule epithelium[l 1]. 
2-2 Biochemical states leading to nephrolithiasis 
I Nephrolithiasis is a complex disorder, involving one or more of the underlying 
biochemical disturbances : 
2.2.1 Hypercalciuria 
Hypercalciuria accounts for about 60% of all renal stones[12], occurring by 
several different pathophysiologic mechanisms[12]: 
2.2.1.1 Absorptive hypercalciuria rAH) 
Increased intestinal calcium absorption in this autosomal dominant disorder 
results in transient hypercalcemia. Subsequent inhibition of parathyroid hormone 
(PTH) reduces renal tubular calcium reabsorption, enhancing urinary calcium 
excretion to restore normocalcemia. Type I-AH is a severe form occurring with 
normal dietaiy calcium intake, whilst type H-AH is a milder form occurring only with 
high calcium intake. 
2.2.1.2 Renal hypercalciuria 
Impaired renal tubular calcium reabsorption accounts for hypocalcemia 
which stimulates PTH release. The secondary hyperparathyroidism mobilizes calcium 
8 
from bone, also augments renal synthesis of vitamin D3 and intestinal calcium 
absorption. Hypercalciuria is exacerbated. 
2.2.1.3 Reabsorptive hvpercalci'uria 
It is caused by primaiy hyperparathyroidism which induces excessive bone 
reabsorption. High PIH stimulates vitamin D3 synthesis, thus enhancing intestinal 
calcium absorption. Hypercalcemia and increased filtered load of calcium augment 
hypercalciuria. 
2.2.2 Hyperoxaluria 
An increase in urinary oxalate excretion predisposes to stone recurrence[13]. 
Three types of hyperoxaluria[l,13] lead to formation of oxalate ciystal, which 
combines with urinary calcium to become very insoluble calcium oxalate: 
2.2.2.1 Enteric hyperoxaluria 
Chronic fat malabsorption in ileal disorders, e.g. bowel inflammation or 
resection, may enhance oxalate absorption and urinary excretion. The excessive free 
fatty acids in the gut due to fat malabsorption bind the calcium in the lumen, leaving 
oxalate free for absorption by the colon, with resultant hyperoxaluriaf 14 ]. 
2.2.2.2 Primary hyperoxaluria 
It is an autosomal recessive disorder of glycine/serine metabolism, contributing 
to overproduction and increased urinaiy excretion of oxalate even on oxalate-
restricted diets. It is characterized by recurrent nephrolithiasis developing to renal 
failure. 
2 2.2.3 Dietary hyperoxaluria 
Associated with oxalate-rich diets like nuts, beans, tomatoes, chocolate etc., 
the hyperoxaluria resolves upon oxalate restriction. Vitamin C overdose can cause 
9 
spurious hyperoxaluria since urinaiy vitamin C breaks down to form oxalate in the 
oxalate assay. 
2.2.3 Hyperuricosuria 
Hyperuricosuria occurs after eating large amount of purine-rich food such as 
meat, or can be due to urate overproduction in gout, myeloproliferative disorders and 
malignancy. About 25% of calcium stone formers exhibit hyperuricosuria[13]. Uric acid 
promotes calcium oxalate crystallization by facilitating nuclei fonnationf 3 ]. In addition, 
it can be adsort>ed to naturally-occurring urinaiy macromolecules such as GAGs, thus 
lowering their inhibitory activities against calcium oxalate crystal growth[ 3 ]. 
2.2.4 Cystinuria 
I T h i s i s 妨 ^tosomal recessive disorder of transmembrane cystine transport in the 
kidneys and intestine[15]. It is characterized by excessive urinary excretion of cystine, 
ornithine, lysine and arginine, owing to a renal tubular reabsoiption defect of these 
amino acids. At physiologic urinary pH, cystine is insoluble, and will precipitate out in 
concentrated urine as hexagonal crystals in patients with cystinuriaf 3 ]. 
2.2.5 Xanthinuria 
Xanthine stones are very rare, and indicates xanthine oxidase deficiency[ 3 ]. 
2.3 Inhibitors of nephrolithiasis 
In reality an overlap of the degree of urine supersaturation exists between normal 
S u b j e c t s m d P a t i e n t s ^ nephrolithiasis. Calcium oxalate in normal urine is four times 
more concentrated than its solubiHty[16]. Only when supersaturation is 7 to 11 times its 
solubility, nucleation initiates. Calcium stone formers excrete more calcium and oxalate 
1 0 
than normal subjects, yet many people having increased urinaiy calcium and oxalate do 
not develop nephrolithiasis, owing to the presence of sufficient organic and inorganic 
inhibitors of renal stone formation in urine. 
Urinaiy inhibitors have been identified for the calcium oxalate and calcium 
phosphate stones but not for the urate stones[ 3 ]. Citrate, glycosaminoglycans (GAGs), 
pyrophosphate, nephrocalcin and other high molecular mass compounds such as 
Tamm-Horsfan protein are the main urinary inhibitors of calcium-oxalate 
nephroUthiasis[17,18,19]. Magnesium, citrate, pyrophosphate, and nephrocalcin make 
up the majority of urinaiy inhibitors against calcium phosphate stone fonnation[19]. 
Table 3 summarizes the roles of different urinary inhibitors of nephrolithiasis. 
1 1 
Process of nephrolithiasis Urinaiy inhibitors that act against the process 
Supersaturation~“ Citrate, magnesium ' ~ 
Nucleation Glycosaminoglycans (GAGs) 
Crystal growth/aggregation Citrate, magnesium, pyrophosphate, uropontin, 
Tamm-Horsfall protein, nephrocalcin 
Table 3 : Urinary inhibitors of nephrolithiasis 
(modified from Balaji KC, Menon M. Mechanism of stone fonnation. Urolithiasis 
1997;24(1):1-11) 
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3. Biochemistry of Citrate 
3.1 Basic aspects 
Citrate, a central component of citric acid cycle (Krebs' cycle), is ubiquitous in the 
human body. It provides an energy source for the vital organs, kidneys and Uver, which 
are the main sites of citrate metabolism[20]. 
Citric acid is a tricarboxylic acid (C^Oy, molecular mass = 192.1 g) with pKa's 
of 2.9, 4.3 and 5.6 . Therefore, at physiologic pH in plasma, citrate exists 
predominantly as free triply-charged ions, freely filtered in the glomeruli. Normal 
plasma citrate concentration ranges from 0.05 to 0.30 mmoI/L [20]. 
Dietary citrate is present in the form offree citric acid in a variety of food，such as 
fruk juice (from lemon, orange etc.), vegetables, tea, wine, beer, cheese, bread, 
margarine, edible oil and meat products. Citric acid esters are also found in wine. 
P l a s m a c i t r a t e i s d e r i v e d Primarily from oxidative metabolism. The extent to 
which plasma citrate derives from dietary citrate has not been well studied. 
Gastrointestinal malabsorption of citrate is not thought to contribute to 
nephrolithiasis[21]. Researchers have demonstrated that dietaiy citrate is rapidly 
absorbed from the gastrointestinal tract in both normal subjects and patients with 
idiopathic hypocitraturia[22]. They have also shown that a small portion (-10%) of an 
oral citrate load is excreted without metabolism in the urine[23]. The absorbed citrate is 
predominantly metabolized to bicarbonate, which thus alkalinizes the urine and causes 
cftraturia (in large part secondary to the alkaline load by a mechanism discussed in the 
section 3.4 ) to reduce recurrent stone formation. This is the basis of oral citrate 
therapy for nephrolithiasis. 
1 3 
3.2 The role of kidney in citrate metabolism 
Plasma citrate is freely filtered in the glomeruli. Citrate is predominantly 
reabsorbed in the proximal tubules, mediated by a carrier (figure 1) in the brush border 
of the tubular membranes[20]. This non-specific citrate carrier actively transports 
citrate，succinate, x-ketoglutarate and other dicarboxylate anions, from the tubular 
fluid into the tubular cells. All these organic anions competitively inhibit the transport of 
each other. Citrate transport is sodium-ion dependent: three sodium ions are co-
transported with one citrate ion. An insignificant portion of citrate is reabsorbed from 
the post-glomerular blood and metabolized inside the tubular cells (figure 2). 
Citrate metabolism occurs inside the proximal tubular cells through 
intramitochondrial oxidation[20]. Reabsorbed citrate accumulates in the proximal 
tubular cytoplasm, where some of the citrate is metabolized to oxaloacetate and acetyl 
CoA in the presence of citrate lyase. A tricarboxylate carrier (figure 1) in the inner 
mitochondrial membrane of the proximal tubular cells transports the cytoplasmic citrate 
into the mitochondria. Inside the mitochondria, citrate is oxidized into water and C02, 
providing energy for the kidneys. The rate of citrate transport by the tricarboxylate 
carrier is controlled by (1) the pH gradient across the inner mitochondrial membrane 
which is the determinant factor, and (2) the cytoplasmic and intramitochondrial citrate 
concentrations. During oxidative phosphoiylation hydrogen ions are actively pumped 
out of the mitochondrial matrix, with hydroxyl ions left inside the mitochondria. A pH 
gradient is established across the inner mitochondrial membrane so that the matrix 
space is alkaline compared with the exterior[20]. This pH gradient provides the driving 
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Proximal Tubule Ceils LUMEN 
� I 
i 3 
/ ^ + Citrate3 
: ^ ^ ^ I 
CL : Citrate lyase ； AcCoA : Acetyl-CoA ； OAA : Oxaloacetate 
Figure 1 : Model of proximal tubule cell handling of citrate. 
(adapted from Wright EM. Transport of caiboxylic acids by renal membrane 
vesicles. Annu Rev Physiol 1985;47:127-141) 
1 5 
I 
Cel l s of 
� p r o x i m a l tubu le 
f ^ s H z , , ’ , ^ < Peritubular | 
署 H z " F i l t e red S t r a f e from ； 
flL V ci t ra te 0cid post-glomerular S 
r r S ^ T F ^ ^ t ^ I 
1 一矗 �� Mitochondria ！ I H ^ 4 @ � � � + I 
Circled numbers are representative values in humans in jimol/min. 
Citrate is removed from both tubular fluid and postglomerular blood and is 
metabolized in tubular cells. 
Figure 2 : Characteristics of citrate handling by nephron. 




forCe f 0 r A T P 柳 版 奴 T h e 狎 胁 the mitochondrial pH gradient facilitates the more 
rapid the mitochondrial uptake and renal utilization of citrate, reducing the urinaiy 
citrate excretion. Fractional excretion of citrate can be enhanced by (1) inhibiting 
mitochondrial citrate metaboUsm, mediated via a decrease in the mitochondrial pH 
gradient，or (2) promoting intracellular citrate synthesis from precursors. Systemic 
acid-base imbalance changes the proximal tubular reabsorption of citrate by affecting 
the mitochondrial pH gradient, and is the most important cause of altered citrate 
metabolism and excretionfl 8]. 
3.3 The role of kidney in citrate excretion 
In human, 10 to 35% of the freely filtered citrate escapes tubular reabsorption 
and is excreted in urine[20]. Citrate represents the most abundant organic anions in 
nrine[24]. It chelates with calcium ion (as much as 70%) in urine, preventing the 
precipitation of calcium salts especially in alkaline urine. 
Since tubular secretion of citrate is minimal, urinaiy citrate level is affected mainly 
by proximal tubular reabsorption. Citrate reabsorption exhibits a diurnal variation, with 
the lowest urinaiy citrate level in early morning, and the highest level in the afternoon 
I [ 2 5 ] T h e C a u s e o f 她 variation is not clear. Urinaiy citrate output is negligibly affected 
by variations in the amount of filtered citrate, because plasma citrate level is relatively 
constant[25]. As mentioned above, the urinaiy citrate excretion is remarkably sensitive 
to changes in the systemic acid-base balance. 
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3 4 Altered urinary citrate excretiof 
The various causes of altered urinaiy citrate excretion are as follows: 
3.4.1 Systemic acid-base imbalance 
Systemic metabolic alkalosis enhances urinaiy citrate excretion, whilst metabolic 
acidosis reduces citrate excretion[20]. 
Metabolic alkalosis causes the cytoplasrmc pH in proximal tubules to rise, 
reducing the mitochondrial pH gradient. Subsequently, the tricarboxylate carrier is 
inhibked, slowing down the mitochondrial citrate oxidation. Cytoplasmic citrate in the 
proximal tubules accumulates, leading to reduced tubular reabsoiption and peritubular 
uptake of citrate (figure 3). Urinaiy citrate increases, up to 60% of the filtered citrate 
may appear in urinepO]. 
Exactly the opposite mechanism prevails in metabolic acidosis. This is exemplified 
by the distal acidification defect in the complete form of distal renal tubular acidosis 
(dRTA)，which commonly presents with systemic metabolic acidosis[26]. 
Hypocitraturia accompanying dRTA is one of the factors leading to nephrolithiasis (see 
section 4.3). Hypokalemia causes intracellular metabolic acidosis in the renal cortex. 
Consequently, hypocitraturia occurs by the same mechanism as in systemic metabolic 
acidosispO]. 
3.4.2 Chronic diarrhoeal syndrome 
Gastrointestinal disorders like small bowel inflammation, colitis, bowel resection, 
and post-gastrectomy state produce this syndromef 18,27]. Chronic diarrhoea causes 
— p o t a s s i u m and bicarbonate losses, leading to hypokalemia and systemic 
metabolic acidosis. Severe hypocitraturia may develop, correlating with the degree of 
diarrhoea. 
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Figure 3 : Influence of changing mitochondrial pH gradient on citrate reabsorption and 
excretion during acid base alterations. 
(adapted from Simpson DP. Citrate excretion: a window on renal metabolism. Am J 
Physiol 1983;244:F223-F234) 
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3.4.3 Thiazide-induced hypocitraturia 
Thiazides are used to treat hypercalciuric calcium nephrolithiasis by reducing 
urinary calcium excretion. Nevertheless, they may inhibit citrate excretion, probably by 
causing hypokalemia and intracellular acidosis[28]. Unchecked hypocitraturia may 
oppose the therapeutic effect of lowering calcium excretion, and may result in relapse 
of nephrolithiasis. 
3.4.4 Vitamin D overdose 
Vitamin D inhibits the intramitochondrial citrate metabolism, augmenting urinary 
citrate excretion[20]. 
3.4.5 Idiopathic hypocitraturia 
The exact cause for the hypocitraturia in some patients is unknown[18]. 
Postulations include strenuous physical exercise, diet high in animal protein with 
sulphur-containing amino acids (production of an acid load), active urinary tract 
infection (bacterial enzymatic decomposition of citrate), high sodium intake in the 
setting of low potassium intake (induction of mild metabolic acidosis), and intestinal 
malabsorption of citrate. 
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4- Hypocitraturia as a Risk Factor of Nephrolithiasis 
4.1 Experimental and clinical evidence on the role of citrate as a 
stone inhibitor 
Sabbatini in 1901 postulated that citrate chelated with calcium to prevent blood 
coagulationt29]. It was not until 1934 that Hastings et al obtained evidence for the 
existence of such a complex, thereby providing the basis for a possible role of citrate in 
nephrolithiasis[30]. Researchers in the 1930s and 1940s discovered that calcium stone 
formers excreted less citrate than normal subjects[31]. Short et al in 1942 suggested 
I t h a t nephrolithiasis was the consequence of an impairment of a normal renal mechanism 
which adjusted citrate output to accommodate increases in calcium excretion[32]. They 
believed that reduced urinary citrate excretion could be corrected by appropriate 
t therapeutic regimens, thereby decreasing the probability of stone recurrences. 
Late; researchers claimed that hypocitraturia might explain the formation of renal 
stones[33]. Though the published results were conflicting, recent studies have largely 
confirmed that stone formers excrete significantly less citrate[34]. Meyer and Smith in 
1975 and Ryall et al in 1981 discovered that citrate directly inhibited calcium oxalate 
ciystal growth and aggregation in vitro respectively[35,36]. Parks and Coe in 1986 
demonstrated a very marked difference between the stone formers and nonnals in the 
ratio of calcium/citrate excretion[37], verifying the earlier findings of Shoir et al in 
1942 [32]. 
Pak et al in 1985 discovered that treatment with potassium citrate up to 4 years 
produced a decrease in nephrolithiasis in 97.8% and remission in 79.8% of patients with 
hypocitraturia[27]. 
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Minisola et al in 1989 reported their studies on citrate metabolism in a large 
group of normal subjects and stone patients[38]. Consistently the 24-hour urinaiy 
citrate and the fasting citrate/creatinine ratio were remarkably reduced, whereas the 
tubular citrate reabsorption was significantly increased in renal stone patients compared 
to normal controls. The serum citrate concentrations and filtered loads were similar in 
the two groups. No abnormality in the intestinal handling of citrate was found in the 
patients. Their findings supported the renal involvement in the pathogenesis of 
hypocitraturia in patients with nephrolithiasis. 
Thus, concluding from the above evidence, it would appear that hypocitraturia is 
a predisposing factor in the pathogenesis of nephrolithiasis. 
4.2 Mechanism of the inhibitory activity of citrate against 
nephrolithiasis 
Balaji and Menon in 1997 reviewed that urinaiy citrate plays its role as a 
complexor and inhibitor against calcium oxalate and calcium phosphate stone formation 
[3 ] . 
Urinaiy citrate chelates potently with up to 70% of calcium ions to form a stable 
soluble complex, thus reducing both the free ionic activity and supersaturation of 
calcium oxalate and calcium phosphate[39]. Citrate exerts its maximal effect at pH 6.5 
If citrate complexation of calcium is sufficient to bring undersaturation, prefoimed 
calcium salts would dissolve[39]. 
Citrate directly inhibits heterogeneous nucleation (by monosodium urate), 
aggregation and growth of calcium oxalate crystals[40,41]. Lieske and Toback in 1996 
I discovered that calcium oxalate monohydrate (COM), the commonest stone crystal, can 
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bind within seconds to sialic acid-containing glycoproteins on the apical surface of 
renal epithelial cells in culture, postulating one mechanism of crystal retention in renal 
tubules[42]. They found that urinary anions like citrate and GAGs compete with COM 
for binding onto the surface, and thus prevent crystal adherence. 
Citrate also inhibits calcium phosphate crystallization and crystal growth. Grases 
F et al. in 1993 claimed that citrate is the most effective substance for preventing 
phosphate particle formation[43]. Phosphate crystals represent an essential hetero-
geneous nucleus for motivating calcium oxalate stone formation. 
Furthermore, citrate alters the shape and composition of crystals formed on 
epithelial linings, casts or other crystals, thus limiting further ciystal growth[44]. 
Citrate restores the inhibitory reactivity of Tamm-Horsfall protein[45]. When 
expressed relative to molecular mass, citrate inhibitory activity is less prominent than 
that of Tamm-Horsfall protein, nephrocalcin, pyrophosphate, and glycosaminoglycans. 
Nevertheless, at physiologic concentration in urine, citrate is present in much greater 
amount than these inhibitors, thus is effective for preventing nephrolithiasis[ 18]. 
4.3 Clinical conditions associated with hypocitraturia in 
nephrolithiasis 
Among the clinical conditions manifesting hypocitraturia previously discussed in 
the section 3.4，metabolic acidosis plays a prominent role in producing hypocitraturia 
among Western patients with calcium nephrolithiasis. It accounts for hypocitraturia 
occurring in the complete and incomplete forms of distal renal tubular acidosis[26], 
thiazide therapy[28]，and chronic diarrhoeal state[ 18,27]. Some idiopathic 
hypocitraturic states mentioned previously are associated with acid-base imbalance" 8]’ 
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contributing to another category of calcium nephrolithasis. 
NephrolitWasis and nephrocalcinosis (precipitation of calcium salts in the 
substance of the kidney) present usually in the complete form of distal tubular 
acidosis[26]. Defective hydrogen-ion excretion in the distal tubules produces alkaline 
urine, and hyperchloremic metabolic acidosis causes hypocitraturia, skeletal loss of 
calcium and phosphate, and impaired tubular calcium reabsorption. Subsequent 
hypercalciuria coupled with alkaline urine, augment calcium phosphate crystallization 
by increasing the ionic form of phosphate and reducing the solubility of calcium 
phosphate. Hypocitraturia accounts for insufficient citrate complexation of urinary 
calcium. Moreover, supersaturation from hypercalciuria, accelerated by hypocitraturia, 
may also augment calcium oxalate crystallization. Typically, calcium phosphate 
(hydroxyapatite) is the dominant stone constituent, with calcium oxalate as a minor 
component[26]. 
In the incomplete form of distal renal tubular acidosis, calcium nephrolithiasis 
may be manifested without nephrocalcinosis [26]. Less severe hypocitraturia or 
normocitraturia may be present, together with moderately elevated urinary calcium and 
urine pH is usually high normal. 
Nephrolithiasis is not associated with proximal renal tubular acidosis or with 
hyporeninemic hypoaldosteronism[26]. Hypocitraturia may be caused by acidosis. 
Nevertheless, urinary calcium is usually low due to bicarbonaturia in proximal renal 
tubular acidosis, and renal insufficiency in hyporeninemic hypoaldosteronism (normal 
urine pH also). 
Nephrolithiasis in the chronic diarrhoeal syndrome is multifactorial[46]. 
Hypocitraturia, low urine output (increased intestinal fluid loss), hypomagnesiuria 
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(intestinal malabsorption of magnesium), and hyperoxaluria (present if intestinal 
disorder associated with fat malabsorption) contribute to renal stone formation. 
Furthermore, low urine pH (less than 5) impairs dissociation of uric acid and promotes 
uric acid stone formation, since uric acid is less soluble than the urate salts. 
Table 4 summarizes the diagnostic criteria for the main forms of hypocitraturia in 
nephrolithiasis. 
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Complete dRTA Incomplete dRTA Chronic diarrhoeal Thiazide-induced 
syndrome hypocitraturia 
Serum: 
Potassium -l N 山 山 
Chloride 个 N N/f i 
Bicarbonate 4 N N 4 个 
Urine: 
pH 个 个 / N i N 
Calcium 个 个 / N 山 i 
Citrate I 山山 山 
(N= normal;个=increase; 4= decrease) 
Table 4 : Diagnostic criteria for the main forms of hypocitraturia in nephrolithiasis, 
(adapted from Pak CYC et al. Ambulatory evaluation of nephrolithiasis: classification, 
clinical presentation and diagnostic criteria. Am J Med 1980;69:19-30 ) 
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5. Analytical Methods for Urinary Citrate Assays 
5.1 Enzyme-spectrophotometric methods 
The traditional enzyme-spectrophotometric method (Moellering and Gruber 
1966) uses the principal enzyme citrate lyase, which is highly specific for citrate[47]. 
Citrate in the presence of Zn2+ at pH 8.2 is converted to oxaloacetate and acetate by 
citrate lyase. Oxaloacetate in the presence of malate dehydrogenase (MDH), NADH 
and is reduced to L-malate, whilst one mole of NADH is oxidized to NAD+ for 
each mole of citrate reduced. Since NADH absorbs light at 340 nm but NAD+ does not, 
citrate can be quantitated by absorbance change of the reaction mixture at 340 nm 
before and after incubation with citrate lyase. Some oxaloacetate may be 
decarboxylated to pyruvate by oxaloacetate decarboxylase, a frequent contaminant in 
the citrate lyase preparation. This problem is overcome by incorporating lactate 
dehydrogenase (LDH) into the reaction mixture. Pyruvate is reduced to L-lactate by 
NADH and stoichiometric amount of NAD+ is produced. The net NADH consumed is 
stoichiometrically related to the original citrate in the specimen. 
Recently a modified citrate lyase method[48] was successfully applied for urine 
citrate quantitation by Petrarulo et al. in 1995. The modification relies on the use of 
phenylhydrazine as a carbonyl trapping and chromophore agent. Both the a-keto acids, 
i.e. oxaloacetate and pyruvate, formed in the presence of citrate lyase and oxaloacetate 
decarboxylase, react rapidly with phenylhydrazine at slightly acidic pH (optimal 6.5) to 
produce the corresponding a-keto acid-phenylhydrazones and water. Phenylhydrazones 
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exhibit strong UV-absorbing property. Urinary citrate can be quantitated by measuring 
the increase in absorbance at 330 nm. 
This new method owns the following advantages over the traditional one[48]. 
Firstly, it does not require the use of additional enzymes (MDH, LDH) or cofector 
NADH for coupling reaction. Secondly, it is twice as sensitive as the traditional one 
because the specific absorptivity of oxaloacetate phenylhydrazone (6330^ 12.1 L.mmol 
-1.cm_1 ) is double that of NADH (8340 = 6.3 L.mmol ^.cm'1 )• Thirdly, it is more 
economical due to reduced reagent cost. 
Preincubation of urine samples with phenylhydrazine before the enzyme reaction 
ensures complete binding of endogenous oxaloacetate and pyruvate with phenyl-
hydrazine for blanking. This step also minimizes the shift of absorbance baselines for 
both sample blanks (0 to 0.2 mA/min) and enzyme reacted samples (0 to 0.3 mA/min) 
during incubation with citrate lyase. Nevertheless, the total incubation time may be long, 
ranging from 25 to 55 minutes, depending on the volume of sample and amount of 
enzyme added. This new method correlates well with the traditional citrate lyase and 
HPLC methods[48]. Table 5 compares the analytical performance between the new and 
traditional citrate lyase methods[48]. 
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Quantitation of urinary citrate Traditional method a New method b 
using citrate lyase 
Imprecision (%C. V.)： 
(1) at 0.96 mmol/L (n=10) 5.0 2.0 
(2)at4.17mmol/L(n=10) 1.8 1.0 
Mean recovery 土 1 SD(%) 100.5 土 3.3 100.7 士 2.2 
(spiked with 2.0 mmol/L citrate) 
Upper limit of linearity (mmol/L) B 8 
Sensitivity (A.mmol^.L) 0.125 0.228 
Detection limit (mmol/L) = conc. at which 0.10 0.08 
%C.V=10) 
Baseline drift (mA/min) -(0.3 to 1.1) 0 to 0.3 
(A =absorbance unit) 
a Moellering & Gruber 1966 
b Petrarulo^a/. 1995 
Table 5 : Comparison of the analytical performance between the new and traditional 
citrate lyase methods 
(modified fiom Petiarulo M, et al. Citrate in urine determined with a new citrate lyase 
method. Clin Chem 1995;41(10):1518-1521) 
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5.2 High performance ion chromatography 
High performance liquid chromatography (HPLC) facilitates a rapid technique 
for the separation and determination of organic acids. Three separation principles have 
been used, namely ion-suppression chrortiatography, ion-exchange chromatography and 
reversed-phase chromatography of the derivatized products, for quantitation of citrate 
in body fluids, fruit juices and pharmaceuticals. 
Singh and Nancollas in 1985 developed a fast high-performance ion-
chromatographic (HPIC) method for analyzing urinary citrate within 11 minutes[49]. 
Adding acids or acidic buffers to the mobile phase lowers the pH and suppresses the 
ionization of the acidic functional groups of the solutes. Ionization suppression-aided 
separations rely on hydrophobicity of the analytes. Hydrophobic interactions of the 
hydrocarbonaceous moiety of the organic acids with the octadecyl chains of the 
stationary phase provide the basis of retention. Consequently, relatively polar 
substances can be separated on C18-silica gel columns with neat aqueous eluents of the 
appropriate pH. HPIC analyses are made by injecting lOOpL of 50 or 100-fold diluted 
urine into the injection port after pre-filtering through 0.22 \im pore size Millipore 
filters. The retention time of citrate is 8 minutes. Peak heights in the urine samples are 
compared with standard citrate solutions, together with similar amounts of oxalate, 
sulphate, and phosphate as those in urine. The citrate peak can be confirmed if 
necessary, by treating the same sample with citrate lyase before injecting into the 
column. 
This HPIC shows excellent correlation (the correlation coefficient r=0.9992; y=x-
0.0017) with the traditional enzyme-spectrophotometric method[49]. Its mean recovery 
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is 99.4%. Excellent precision is observed in the citrate analyses of both fresh and 
frozen (for 8 days) urine samples. The detection limit of urinary citrate is 0.05mmol/L. 
Linearity of the calibration curve is very good and up to 0.25mmoI/L. 
5.3 Capillary electrophoresis and indirect ultraviolet absorbance 
detection 
Capillary electrophoresis (CE) is a recently developed technique for separation of 
biomolecules, by means of very high voltage in solution[50]. Components are well 
resolved across a narrow bore capillary which reduces the building up of heat. Since 
convection and free flow within the capillary are minimized, high performance 
electrophoresis can be performed in buffer alone without agarose or polyacrylamide gel. 
CE is highly sensitive due to the great number of theoretical plates obtained. It can 
detect major peaks with minimal peak tailing and distortion. A linear polymer coated on 
the capillary inner wall eliminates electroendosmosis. Consequently, the electrophoretic 
mobility of any ion (sample or buffer) under a given electric field depends strictly on the 
ratio of molecular mass and charge. 
The retention time (Rt) is expressed as : Rt = [ k . (M273 )/z] where M= molecular 
mass, z= charge at given pH and k= constant. 
Recently capillary electrophoresis has been applied for quantitation of urinary 
anions. Holmes in 1995 has developed a method for measuring urinaiy citrate and 
oxalate simultaneously with CE and indirect UV absorbance detection[51]. The anions 
injected as a small plug into thin glass capillary are displaced rapidly towards an anode 
generated by a negative power supply. This movement is enhanced by the use of a 
modifier of electroosmotic flow, which results from electrolyte interactions with the 
1 1 
charge built up on the capillary wall. Separations are conducted on a polyimide-coated 
fused-silica capillary at 15 - 18 kV and constant current. Indirect UV absorption 
detection mode is employed. A chromophoric electrolyte e.g. chromate is used for 
detecting rapidly migrating anions. The electrolyte displacement by urinary citrate and 
oxalate in the detection window produces a negative peak. Indirect absorbance 
detection has the merit that it acts as a universal detection mode, allowing the 
identification of ions with a low absorptivity. 
The described method is rapid, accurate and precise[51]t The mean retention 
times of citrate and oxalate are 4.50 and 4.02 minutes respectively. Both their detection 
limits are 7 mg/L (0.036 mmol/L for citrate). Total imprecisions (C.V.) are 1.2 - 5.6% 
for three urine samples with citrate concentrations ranging from 0.42 to 4.48 mmol/L. 
The mean recovery of citrate is 99.3% 土 2.6% for 0.52 mmol/L added and 100.5% 土 
2.2% for 2.60 mmol/L added. A correlation of r=0.97 (y= 0.92x 斗 31.2) is observed 
between the citrate determinations by CE and traditional citrate lyase method. 
5.4 Comparison on the analytical methods 
Table 6 summarizes the comparison of different analytical methods for urinary 
citrate. For quantitation, of urinary citrate both the high-performance ion-
chromatography and capillary electrophoresis correlate well with the enzyme-
spectrophotometric methods. The former techniques are more specific and sensitive, 
with shorter analysis time than the citrate lyase one. Furthermore, future developments 
in the HPIC and CE instrumentation may permit simultaneous analysis of multiple 
anions in urine and serum. This advance may brighten the prospects for rapid studies of 
lithogenic and inhibitory substances in urine from patients with nephrolithiasis. 
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Nevertheless, expensive and sophisticated instruments are required. 
Owing to lack of HPIC and CE analyzers in the working place, an automated 
citrate lyase-phenylhydrazine method using Cobas Fara was developed in this project 
for urinary citrate determination. It is accurate, specific, reproducible and rapid, with a 
running time of 15 minutes. In addition, this method is more sensitive than the 
traditional citrate lyase method. 
3 3 
Manual enzyme High performance Capillary electrophoresis 
spectrophotometric ion chromatographyb & indirect UV absorbance 
(traditional citrate lyase detection0 
method)a 
• • • . • , -
Imprecision(%C.V) 1.8-5.0 1.5-4.6 1.2-5.6 
Meanrecovery(%) 100 5 99^4 99J 
Detection-limit Ol 0j05 0.036 
(mmol/L) 
Running time (min) 30 11 4.5 
Correlation with the : 099 U97 
citrate lyase method y= x-0.0017 y-0.92x+31.2 
Merit simple facilitates simultaneous multianalysis of urinary 
anions e.g. oxalate, phosphate, GAGs. 
a Moellering & Gruber 1966 
b Singh &Nancollas 1985 
c Holmes 1995 
Table 6 : Comparison of different analytical methods for urinary citrate 
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6. Quantitation of Urinary Citrate 
6.1 Principle of the assay 
The automated citrate lyase-phenylhydrazine method was based on the method 
developed by Petrarulo [48], discussed in the section 5.1. 
10|jL of deproteinized urine samples, aqueous calibrators, and deionised water 
(blank) were respectively mixed and preincubated with lO i^L freshly-prepared working 
phenylhydrazine for 5 minutes in spectrophotometer cuvettes at room temperature. The 
reaction mixture was then diluted with 250^L working Bis-Tris buffer (pH 6.5). After 
mixing, the initial absorbance Ai was measured at 330 nm. IO^iL working citrate lyase 
was pipetted respectively into the buffered reaction mixture. After incubation for 8 
minutes at room temperature, the final absorbance A2 was measured at 330 nm. The 
absorbance changes (AA = A � - A i - AAwaterwank) of aqueous standards were calculated 
and used to establish the calibration curve. The urinary citrate concentration was 
obtained from the calibration curve after evaluating the absorbance change (AA =A2 -
Al - AAwater blank), Or from the formula Csa—le = (AAsan^ - AAwater blank) /(AAfitandard " 
A Awater blank) X Ostandard* 
6.2 Instrumentation 
The main instrument employed for automated urinary citrate quantitation was the 
Cobas Fara II centrifugal analyzer from Roche Diagnostics. Centricon-30 membrane 
filters from Lida manufacturing Corp. USA, were selected for deproteinization. IEC 
Centra-M2 microcuvette desktop centrifuge from International Equipment Company, 
USA, was used for urine centrifiigation. 
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6.2.1 Cobas Fara II centrifugal analyzer 
It is an integrated centrifugal analyzer utilizing the horizontal light-path principle. 
The amounts of sample, diluent and reagents, as well as the sequence of the reaction 
modes and the transfer patterns are user-programmable, making this instrument suitable 
for research and development works. Furthermore, the five optical measurement 
techniques (absorbance, fluorescence polarization, turbidimetiy etc.), permit a wide 
variety of assays to be performed on the single instrument. The built-in computer is 
supplied with software to run analytical programs for endpoint and kinetic studies, 
automatic blanking, and regression analysis. 
According to the assay protocol programmed, the robotic pipettor arms deliver 
samples, randomly select and load several reagents, sample diluent and pretreatment 
solution into thirty disposable cuvettes mounted in a manually-loaded rotor. Each 
cuvette owns two compartments, one for reagent and another for sample and additional 
reagent(s) if required. To minimize carryover, both the interior and exterior of the 
sample probe are washed after each aspiration or dispensing cycle. The sample and 
reagent are kept separate until the rotor accelerates and mixes by means of vibration 
and braking. The rotor can then be stopped for pipetting another reagent for multi-step 
analysis. The rotor accelerates and the next reaction starts. Temperature of the rotor is 
user-programmable to 土 0.1 °C , being controlled by temperature-controlled air-flow 
over 20 to 50 °C. 
The absorbance measurements apply a horizontal placement of cuvettes relative 
to the light path. This feature permits smaller reagent volume and compensates any 
pipetting error of reagent volume. Besides, the optimal photometric range can be varied 
by the reaction volume used. The wavelength is selected by a motor-driven holographic 
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grating monochromator (k range: 285 画 750 nm). Bichromatic blanking can also be 
programmed into the analyzer. 
6.2.2 Centricon-30 membrane filters 
The anisotropic membrane is made up ofpolysulfone, comprising a very thin and 
dense skin laid on top of a macro-porous support. Centrifugal force drives solvents and 
low-molecular mass solutes through the membrane into the filtrate vial. Macro-solutes 
(proteins and hemoglobin) above the membrane cut-off pore size (molecular weight 
30,000) are retained in the sample reservoir. The spin time for this model is up to 30 
minutes at room temperature. Prolonged centrifugation may cause membrane damage 
and leakage. 
A centrifuge with centrifugal force not exceeding 2，500g was used (maximal g 
quoted for Centricon-30 filters = 5,000g [52]). The amount of albumin claimed to be 
retained by a 30,000 molecular weight cut-off filter is over 98% [52], The filter is not 
reusable, and the maximal sample loading volume is 2.0 mL . 
6.2.3 IEC Centra-M2 microcuvette desktop centrifuge 
It is a fixed-angle desktop centrifuge for microcuvette centrifugation of urine 
samples before deproteinization. It can generate a maximal centrifugal force greater 
than ten thousand gravitational force when fully loaded. The spin speed is manually 
selected. 
6.3 Preparation of reagents and standards 
6.3.1 Reagents and chemicals required 
Analytical reagent-grade chemicals were used. Water for reagent preparation and 
dilution was deionized and distilled. 
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The first five materials below were purchased from Sigma Chemical Co. (St. 
Louis, MO, USA), whilst the sixth was brought from the British Drug Houses Ltd. 
(Poole, Dorset England): 
6.3.1.1 Citrate lvase fEC 4 1.3.6^ from Enterobacter aeroeenes 
(Sigma product number: C-0897, Lot: 56H1131 ) 
A vial containing 50 U in 179 mg lyophilized powder (i.e. 0.28 U/mg solid) was 
used. Apart from the enzyme, the other constituents were bovine serum, sucrose, 
magnesium sulphate and EDTA. One unit will convert 1.0 jumol of citrate to 
oxaloacetate per minute at pH 7.6 at 25°C. It is extremely hygroscopic. Store at 2 to 
8°C. Avoid skin contact and inhalation. 
6 3 1.2 Citric acid monohvdrate (CJHrOt.H^Q, formula weight = 210.1 ) 
(Sigma product number: C-1909，Lot: 115H1018 ) 
The ACS reagent (500 g/bottle) with assayed purity 99.8% was used for making 
standards. Store at room temperature. Be cautious of its irritation to respiratory system 
and skin, and its risk of damages to eyes. 
6.3.1.3 Phenylhydrazine. free base (CeftN2，formula weight = 108.1，density - 1.10 
g/mL) 
(Sigma product number: P-6766, Lot: 45H3658 ) 
This concentrated dye solution (50mL/bottle) stored inside brown bottle under 
argon at room temperature, is air and light sensitive. It is toxic, may cause cancer and 
heritable genetic damage. It is also combustible and causes burns. Never inhale its 
vapour ！ Protective clothing, gloves and eye protection must be worn. 
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6.3.1.4 Bis-Tris |Bis(2-hydroxyethyl)imino4ris(hydroxymethyl)-methane] 
(CgHwNOs, free base, formula weight = 209.2 ) 
(Sigma product number: B-9754, Lot: 105H5702 ) 
This buffer (25 g/bottle, minimum purity; 98%) has a pKa = 6.5 at 25°C and an 
useful pH range from 5.8 to 7.2. Store at room temperature. 
6.3.1.5 Sodium azide (NaN3, formula weight = 65.01 ) 
(Sigma product number: S-2002, Lot: 56C-0263, minimum purity 99.0%) 
This chemical is very toxic. Avoid contact with skin and clothing. It is explosive 
on contact with metal. It must be stored inside a locked cabinet at room temperature. 
6.3.1.6 Zinc sulphate heptahvdrate ( ZnS04.7H20, formula weight = 287.56 ) 
(BDH product 702450, 500 g/bottle, analytical reagent, minimum purity: 
99.0%) Store at room temperature. 
6.3.2 Preparation of stock aqueous citrate standards 
6.3.2.1 Aqueous citrate stock standard (8.0 mmol/L) 
1.6808 g citric acid monohydrate was accurately weighed by means of a 
calibrated electronic balance, and dissolved in about 500 mL deionised water in a 1000 
mL volumetric flask. Deionized water was added to exactly the 1000 mL mark on the 
flask, and the solution was well mixed. Prepare it fresh each time new working 
standards are made since it deteriorates within 1 month at 4 °C. 
6.3.2.2 Aqueous citrate stock standard (1.0 mmol/L) 
0.2101 g citric acid monohydrate was accurately weighed and dissolved in 1000 
mL deionized water following the same procedure above. 
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6.3.3 Preparation and stability of working reagents and standards 
6.3.3.1 Working aqueous citrate lvase (3.33 kU/L) 
50 U (0.179g) stock citrate lyase was dissolved in 15.0 mL deionized water. 1 
mL aliquots were prepared for the working enzyme solutions. They were stable for at 
least 6 months at -40°C or lower temperature. Avoid repeated freezing and thawing. 
Once an aliquot of working citrate lyase has been thawed for use, store it at 4°C and it 
is stable within two weeks. 
6.3.3.2 Working aqueous Bis-Tris buffer (50 mmol/L) 
This 50 mmol/L working aqueous buffer contained 10.46 g/L Bis-Tris, 0.1 
mmol/L zinc sulphate heptahydrate (Zn2+ as cofactor for citrate lyase) and 0.2 g/L 
sodium azide (as preservative) dissolved in deionized water. Gloves must be worn when 
handling sodium azide. The working buffer was adjusted to pH 6.5 with 12 M HC1 
using the Corning pH meter. It was stored at 4°C, and stable for at least 3 months. 
6.3.3.3 Working aqueous phenvlhvdrazine solution (246 mmol/L) 
Concentrated phenylhydrazine is highly poisonous. Avoid skin contact with it. 
Wear gloves when pipetting it. The working dye solution must be freshly prepared by 
diluting 50 ^L of concentrated phenylhydrazine with 2.0 mL deionized water inside a 
safety cabinet. The working dye solution must be used within 4 hours. 
6.3.3.4 Working aqueous citrate standards (4.0, 2.0, 1.0, 0.50, 0.25’ 0.10，0.08 and 
0.05 mmol/L) 
4.0, 2.0 and 0.08 mmol/L working aqueous citrate standards were prepared by 
diluting respectively 50.0，25.0 and 1.0 mL of 8.0 mmol/L stock standard (using 
volumetric pipette) exactly to 100 mL with deionized water in 100 mL volumetric 
flasks. They were well mixed and clearly labelled. 0.50，0.25 , 0.10 and 0.05 mmol/L 
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working aqueous citrate standards were prepared by diluting respectively 50.0， 
25.0，10.0 and 5.0 mL of 1.0 mmol/L stock standard (using volumetric pipette) exactly 
to 100 mL with deionized water in 100 mL volumetric flasks. They were well mixed 
and clearly labelled’ Each working standard was added with 3 drops of 6 M HC1 as 
preservative. They were stored in labelled brown glass reagent bottles at 4°C and stable 
for 3 months. New working standards were run with the current ones to verify validity 
(士 0.5%) before being placed in service. 
6.4 Specimen collection & storage 
Owing to diurnal variation in urinary citrate excretion, and comparison between 
daily urinary calcium and citrate output, 24-hour urine specimens were required in this 
project. 
Each patient or control subject was given a 3-litre plastic collection bottle 
containing 10 mL of 12M hydrochloric acid, with an attached written warning “Be 
cautious of corrosive preservative insider He/she was instructed how to collect a 
24-hour urine sample correctly. Completeness of 24-hour urine collection is critical for 
the accuracy of the study. 
Being essential for sample collection, detailed instructions were included on the 
attached patient demographic sheet on the bottle: 
(1) the first portion of urine is discarded and the time has to be recorded; 
(2) collect all urine during the following 24 hours in the bottle, and store it in a cool 
place (if possible, in refrigerator) during the collection period; 
(3) the last voiding should be made at the same time as the collection was started on 
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the previous day; 
(4) bring the urine to the laboratory reception bench as soon as possible after 
completing the collection. 
Received specimens were mixed well. Total volumes were recorded. For each 
specimen, 20 mL aliquot was placed in a labelled plastic container with a plastic cover. 
Another 5 mL portion was saved for determinations of urinary calcium, phosphate, 
magnesium, creatinine and urea. The 20 mL-aliquots were frozen immediately at -40°C 
until batch analyses of urinary citrate and oxalate were performed. 
Stored urine samples are stable for one day at room temperature, seven days at 
4°C and three months at -20°C. 
6.5 Specimen preparation 
Deproteinization 
Centricon-30 membrane filters (30,000 molecular weight cut-off membrane 
filters) were employed for deproteinization of all the urine samples[52]. This step 
would prevent light scattering effect of protein molecules from causing high 
background absorbance, and reduce matrix effect when aqueous citrate standards were 
used. 
Urine samples, thawed if frozen, were transferred into microcuvettes and 
centrifuged in IEC Centra-M2 centrifuge. The membrane support base of Centricon-30 
filter was inserted into a filtrate vial. 1 ml of the urine supernatant was then pipetted 
into the sample reservoir of the filter device. The membrane was never touched with 
pipette tip to prevent damage. The sample reservoir was sealed by a retentate vial to 
minimize sample evaporation. It was centrifuged at 2,000g for 15 minutes. At least 100 
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|jL filtrate was collected for the citrate assay. 
The centrifugation speed should not exceed 2,500g to prevent premature 
plugging of the membrane and subsequent very low filtrate output . 
6.6 Assay protocol for urinary citrate 
The following protocol was modified from the manual protocol ofPetrarulo et al 
to establish the test parameters for automating the urinary citrate assay in Cobas Fara 
analyzer: 
GENERAL 
Test code :UCIT 
Measurement mode : Absorbance 
Reaction mode : P-I-R2-A-SR2-tA 
Calibration mode : Linear Regression 
Reagent blank : Reagent/ diluent 
Wavelength : 330 nm 
Temperature : 25.0 °C 
Decimal position : 3 
Unit ; mvnol/L 
ANALYSIS REAGENT POSITION 
P Sample : 10.0 ^L 
Diluent name : H 2 0 
volume : 10.0 ^L working working 
Cleaner cycle : ON Bis-Tris citrate 
Reagent volume : 10 pJL buffer R2 lyase 
I Incubation : 300 seconds \ 
Ml : 100.0 seconds X 1 . 
M2 :300.0 seconds 
R2 Reagent 2 :250 ^L 
A Readings V. J V y | 
First : 5.0 seconds ^ | 
Number :3 
Interval : 5 seconds j 
SR2 Start reagent 2 :10.0 pJL f A j 
I Incubation : 300 seconds V J j 
M3 :100.0 seconds | — ^ | 
M4 : 200.0 seconds 
A Readings 
First : 5.0 seconds 
Number : 6 
Interval : 30 seconds working phenylhydrazine 
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CALCULATION 
Reaction direction : Increase 
Check : ON 
Conversion factor : 1.00 
Offset : 0.00 
Test range Low ； 0.05 mmol/L 
High : 4.0 mmol/L 
Normal range Low : NO mmol/L 
High : NO mmol/L 
Number of steps : 1 
Calculation Step A : Endpoint 
First : 3 
Last : 9 
CALIBRATION 
Calibration interval : Each batch 
Number of standards : 8 
Position of standard 1 :1 
Std 1: 0.05 Std 2: 0.08 
Std 3: 0.10 Std 4: 0.25 
Std 5: 0.50 Std 6:1.00 
Std 7: 2.00 Std 8: 4.00 
Replicate : Duplicate 
Deviation :5 % 
Correction standard : NO 
Reagent range Low : NO A 
High :NO A 
Blank range Low : NO AA 
High : NO AA 
REACTION MOPE 
Name : P-I-R2-A-SR2-I-A 
1 p : Parallel pipetting of sample & working phenylhydrazine 
2 I : Incubation of the sample with dye 
3 R2 : Working Bis-Tris buffer 
4 A : Measurement cycle of reactant blank absorbance 
5 SR2 : Working citrate lyase 
6 I : Incubation of the enzyme reaction 
7 A : Measurement cycle of absorbance of product 
REAGENT RACK 
Position : 5- IS position 5 
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Length of the preincubation period of samples with phenylhydrazine was 
optimized to ensure stable absorbance baseline before the enzyme reaction. This 
preincubation period was monitored spectrophotometrically to check whether any 
endogenous oxaloacetate and pyruvate present in the urine samples reacted completely 
with phenylhydrazine before the citrate cleavage by citrate lyase. 
6.7 Factors affecting the assay performance 
6.7.1 Deproteinization 
The choice of deproteinization method for urine influences the assay efficiency. 
Membrane filtration and acid deproteinization are two common methods. They have 
their own merits and drawbacks. 
Acid deproteinization employing ice-cold 1M perchloric acid is cheap. The 
supernatant is neutralized with 0.3M potassium carbonate. The disadvantages include 
lower sensitivity due to sample dilution and increased ionic strength. 
Membrane ultrafiltration is effective but expensive. Both interfering molecules of 
protein and hemoglobin are retained by the membrane. In contrast to acid 
deproteinization, no salt is introduced and the ionic strength is unaltered. No sample 
dilution by introducing the deproteinizing agent is encountered, and error of dilution of 
sample is avoided. These make it more popular despite its cost. 
6.7.2 Phenylhydrazine 
The X-max values for pyruvate- and oxaloacetate-phenylhydrazone in the pH 6.5 
Bis-Tris buffer are 312 and 316 nm respectively[48]. In aqueous solution, 
phenylhydrazine decomposes slowly into products which absorb light at shorter 
wavelengths than 330 nm. To minimize this interference and corresponding baseline 
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shift in absorbance measurement, the wavelength selected for absorbance measurement 
is 330 nm. Despite some decrease in the assay sensitivity, the application of high-quality 
spectrophotometer in Cobas Fara gives stable and precise absorbance measurements. 
Nevertheless, working phenylhydrazine must be freshly prepared and not be reused 
after four hours. 
6.7.3 Bis-Tris buffer (pH 6.5) 
The reaction mixtures buffered at pH 6.0 and 6.5, in the presence of 251 U/L 
citrate lyase and 4.6 mmol/L phenylhydrazine, have the maximal reaction rates which 
are complete within three minutes[48]. Alkaline pH retards the enzyme reaction. This 
effect was claimed to be attributed to the reactivity of phenylhydrazine towards 
oxaloacetate under different pH conditions. 
6.8 Evaluation of urine citrate assay 
6.8.1 Calibration 
Eight freshly-prepared aqueous working citrate standards were used for 
calibration with duplicate running. The mean absorbance change for each standard was 
obtained and the absorbance change of water blank was subtracted. The calibration 
curve was established by plotting the net absorbance changes against the corresponding 
concentrations of the standard, using the calibration software of Cobas Fara. 
6.8.2 Imprecision study 
6.8.2.1 Sample and reagent pipetting imprecision of Cobas Fara 
It is necessary to check the pipetting imprecision of the instrument before 
proceeding to study the assay imprecision. Precision dye solution was prepared with 
potassium dichromate. The precision test protocol recommended by Roche for sample 
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and reagent pipetting was followed as reference. Absorbance changes of twenty 
aliquots of the precision dye solution were determined in a batch respectively for 
sample and reagent pipetting. The mean, standard deviation and %C.V. of the 
absorbance changes were calculated. 
6.8.2.2 \^ithin-batch imprecision 
Two low controls (about 0.07 and 0.05 mmol/1) was obtained from a newborn. 
A medium control (about 0.70 mmol/L) was collected from a healthy adult. A high 
control (about 4.35 mmol/L) was prepared by spiking a known amount of citrate in a 
normal urine sample. Citrate concentrations of twenty aliquots of the three levels of 
controls were determined in a batch. The mean, standard deviation and %C. V. for each 
control were calculated. 
6.8.2.3 Between-batch imprecision 
The low, medium and high control pools prepared above were aliquoted and 
frozen at -40°C. One aliquot from each control was assayed once each day for twenty 
days. 
6.8.3 Linearity check 
Doubling dilutions were prepared from a spiked urine sample (citrate about 4.3 
mmol/L) with deionized water using volumetric pipettes and flasks. Citrate assay was 
performed (in duplicate) on the dilutions to check the assay linearity over the calibration 
range. 
6.8.4 Recovery studies 
2.0 ml aliquots of a urine sample were spiked with 0.1 ml standard of different 
concentrations. 0.1 ml of deionized water was added to another 2.0 ml aliquot to 
provide a baseline sample. Citrate concentrations were assayed in triplicates. The 
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dilution of the original urine samples was less than 10% to avoid a major change in the 
urine matrix. 
The recovery ratio was evaluated as follows: 
% recovery ~ (measured increase in conc. / expected increase in conc.) x 100% 
where expected increase in conc. == standard concentration x volume of standard 
volume of (sample + standard) 
-standard concentration x 0.1 
2.1 
The acceptable % recovery should be between 90 and 110%, 
6.8.5 Detection limit 
The analytical sensitivity was determined by measuring citrate of a water blank 
for 30 times. The mean AA and S.D. were calculated. The mean plus 3 S.D. of AA 
value was determined, and the corresponding lowest detection limit in mmol/L was read 
from the calibration curve. 
6.8.6 Carryover study 
Within-batch analysis was performed on four identical urine samples of high 
citrate level (HI, H2, H3, H4) immediately followed by another four identical urine 
samples of normal or low citrate level (LI, L2, L3, L4). 
% carryover was calculated by the formula: 
% carryover = L1-(L3+L4V2] x 100% 
[(H3+H4)/2-(L3+L4)/2] 
The acceptable limit should be within 2% carryover. 
6.8.7 Interference studies 
Pyruvate, oxaloacetate, bilirubin, and lipids are potential interfering substances in 
this assay. Protein and hemoglobin interferences should be removed by membrane 
ultrafiltration. The same protocol used for the recovery studies was applied for 
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interference studies, except that the potential interfering substance was spiked 
individually to the urine sample instead of citrate. Interference was calculated from the 
difference between measured citrate concentrations of the spiked and baseline samples. 
A hemolysate from an EDTA-anticoagulated whole blood was prepared by freeze 
and thaw cycles for the study of hemoglobin interference. The subsequent hemoglobin 
concentration was measured (Hb = 7.6 g/dL). Serial hemolysate dilutions were made 
using deionised water as diluent. Interference studies were performed on urine samples 
spiked with hemoglobin, with and without membrane ultrafiltration pretreatment. 
6.8.8 Correlation study 
Forty urine samples were analyzed by both this assay and the traditional citrate 
lyase method (using a citric acid assay kit [53] for the determination of citrate in 
foodstuffs and other materials: cat. no. 139076, Boehringer Mannheim, Indianapolis, 
Indiana, USA) by Cobas Fara. The correlation coefficient (r ) and the least-squares 
regression equation were then evaluated. The citrate assay using the BM citrate lyase 
kit is not designed for clinical use but for food analysis. In this project, this kit served as 
a tool of comparison. 
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7. Results of Evaluation of the Urine Citrate Assay 
7.1 Calibration 
The calibration curve (figure 4) was linear over the calibration range from 0 to 4.0 
mmol/L, covering the physiologic concentrations in human. 
The absorbance of the reagent blank was low and stable throughout the assay. 
The baseline shift (about 0.2 x 10"3 to 0.7 x 10"3 absorbance units/min) was negligible in 
urine samples and aqueous standards. 
The typical change of absorbance against the time before and after starting the 
citrate lyase reaction was illustrated in figure 5. Endpoints were reached at the end of 
enzymatic incubation over the calibration range from 0 to 4.0 mmol/L. 
7.2 Imprecision 
7.2.1 Sample pipetting imprecision of Cabas Fara 
The % C.V. of 20 consecutive sample pipetting trials was 0.9% at 5卩1 level, 
within the acceptable specification of 1.5% suggested by Roche. 
7.2.2 Reagent pipetting imprecision of Cabas Fara 
The % C.V. of 20 consecutive reagent pipetting trials was 0.4% at 150p.l level. 
The recommended value by Roche is less than 2.0% at this volume. 
The study indicated that sample and reagent pipetting by the analyzer was precise. 
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Figure 4 : Calibration curve of the urinary citrate assay 
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Figure 5 : A typical reaction plot by Cobas Fara for the citrate lyase reaction 
(including the plot of the test blank in the course of reaction) 
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7.2.3 Within-batch imprecision 
The results were shown in table 7. 
7.2.4 Between-batch imprecision 
Table 8 summarized the results. The within-batch and between-batch 
imprecisions were within acceptable limits. 
7.3 Linearity 
The linear range (shown in table 9，figures 6 and 7) was between 0.04 and 4.0 
mmol/L, covering the calibration range. 
7.4 Recovery 
The results of the recovery studies were tabulated in table 10. The mean recovery 
of citrate was around 100% at the physiologic range. However, higher % errors 
(greater than 10%) were revealed at the very low (0.05 mmol/L) and very high (5.71 
mmol/L) citrate concentrations. 
7.5 Detection limit 
The mean absorbance change (AA) of the water blanks was 0.011’ whilst one S.D. 
was 0.004. The mean plus 3 S.D. of AA value was 0.023, and the corresponding 
analytical sensitivity read from the calibration curve was 0.04 mmol/L. The imprecision 
(% C.V.) at this level, however was higher than 10 (refer to the results on precision 
studies). 
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Citrate control High Medium Low 
number 20 20 20 20 一 
mean (mmol/L) 4.36 0.71 0.07 0.05 
S.D. (mmol/L) 0.013 0.006 0.002 0.005 
C.V. (%) I 0.3 0.9 3.0 10.0 
Table 7 : With-batch imprecision of the urinary citrate assay 
Citrate control High Medium Low 
number 20 20 20 —— 
mean (mmol/L) 4.29 0.70 0.07 
S.D. (mmol/L) 0.090 0.008 0.004 
C.V. (%) 2.1 1.1 5.9 
Table 8 : Between-batch imprecision of the urinary citrate assay 
Dilution Conc. measured Expected Deviation 
factor (mmol/L) 
conc. (mmol/L) 
yl y2 mean y x (%) 
~ n e a t 4^35 4^35 0 5 HA. NA 
2 2.25 2.28 2.265 2.175 4.5 
4 1.16 1.16 1.16 1.088 6.6 
8 0.59 0.59 0.59 0.544 8.5 
16 0.29 0.30 0.295 0.272 8.5 
32 0.14 0.14 0.14 0.136 3.0 
64 0.07 0.07 0.07 0.068 3.0 
- 0.04 0.04 0.04 0.041 -2.4 
128 0.03 0.03 0.03 0.034 -11.8 
256 0.01 0.01 0.01 0.017 -41.2 
512 -0.01 -0.01 -0.01 0.009 -211.1 
Table 9 : Linearity study of the urine citrate assay 
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Figure 7 : Linearity of the citrate assay over the calibration range 
5 6 
Expected increase in Measured increase in Recovery Mean recovery 
citrate conc. (mmol/L) citrate conc. (%) (%) 
(mmol/L) 
5 J 1 5A0 "89!3 
5.71 4.97 87.0 
5.71 5.02 87.9 88.1 
T!91 1^93 101.1 
1.91 1.91 100.0 
1.91 1.90 99.5 100.2 
CL38 040 105.3 
0.38 0.39 102.6 
0.38 0.39 102.6 103.5 
019 07l9 100.0 
0.19 0.20 105.3 
0.19 0.20 105.3 103.5 
0.048 0.053 110.4 
0.048 0.054 112.5 
0.048 0.053 110.4 ” 1 . 1 
Table 10 : Recovery studies of the urinary citrate assay 
5 7 
The functional sensitivity, if based on the concentration at which % C.V. was 10， 
was 0.05 mmol/L (refer to the results on precision studies). It was chosen as the 
detection limit of this assay. This detection limit was sensitive enough to detept for 
hypocitraturia. 
7.6 Carryover 
The % carryover (shown in table 11) was within acceptable limits. 
7.7 Interference studies 
7.7.1 Pyruvate 
Pyruvate up to 2 mmol/L (shown in table 12) did not interfere significantly 
(within 1 %) with the citrate assay. At higher concentration, it may cause an under-
estimation of citrate. The physiologic range of urinary pyruvate excretion is within 1 
mmol per day. 
7.7.2 Oxaloacetic acid 
There was no significant interference by oxaloacetic acid with concentration up to 
2 mmol/L (shown in table 13). Above this concentration, oxaloacetic acid may cause an 
under-estimation of citrate. 
7.7.3 Conjugated bilirubin 
Conjugated bilirubin up to 0.91 mmol/L did not interfere significantly with the 
citrate assay (shown in table 14). Conjugated bilirubin is not found in normal urine. 
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urine citrate % canyover 
between high and low levels (5.4 & 0.07 mmol/L) 0.05 
between high and normal levels (6.7 & 0.3 mmol/L) 0.06 
Table 11 : % carryover of urinary citrate in the assay 
Pyruvate added (mmol/L) Concentration detected as citrate (mmol/L) 








Table 12 : Interference study of pyruvate on the urinary citrate assay 
Oxaloacetic acid Concentration detected as citrate 






Table 13 : Interference study of oxaloacetic acid on the urinaiy citrate assay 
Conjugated bilirubin Concentration detected as citrate 






0.09 negative interference less than 0.01 
Table 14 : Interference study of conjugated bilirubin on the urinary citrate assay 
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7.7.4 Lipids 
There was no significant interference with the citrate assay by lipid concentration 
up to 1 mmol/L (shown in table 15). At higher concentration, lipids may cause an over-
estimation of citrate. Lipemic urine specimens must be ultra-centrifuged to obtain the 
supernatant for the citrate assay. Untreated specimens are unfit for the assay. 
7.7.5 Protein 
Table 16 compared the results of the interference studies performed on urine 
samples with and without deproteinization by ultrafiltration. Albumin higher than 0.14 
g/L caused a positive interference. This effect was eliminated by membrane 
ultrafiltration. 
7.7.6 Hemoglobin 
Table 17 compared the results of the interference studies performed on 
hemoglobinuric samples with and without ultrafiltration. Hemoglobin more than 0.04 
g/dL produced a positive interference. Membrane ultrafiltration removed this 
interference in hemoglobinuric specimens. 
7.8 Correlation study 
Results in figure 8 obtained by this assay and the BM citrate lyase kit were well 
correlated (r= 0.97, y=0.96x + 0.09). 
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Table 15 : Interference study of lipids on the urinary citrate assay 









Table 16 : Interference study of albumin on the urinary citrate assay 
Hemoglobin added Concentration detected as citrate 
(g/dL) (mmol/L) 
without with membrane 
membrane filtration filtration 






Table 17 : Interference study of hemoglobin on the urinary citrate assay 
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Figure 8 : Comparison between urinary citrate concentrations measured by the 
automated citrate lyase-phenylhydrazine method and by the traditional 
enzymatic method 
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7.9 Discussion on the methodology 
This automated enzyme-spectrophotometric method for quantitation of urinary 
citrate is rapid and convenient. Total analysis time is about 15 minutes. Both the 
accuracy and precision are improved by the reliable Cobas Fara centrifugal analyzer. 
The very low pipetting imprecision of sample and reagent, coupled with the use of 
disposable cuvettes and their horizontal placement relative to the light path, account for 
higher reproducibility and sensitivity. 
The analytical performance of this automated assay can be considered as 
satisfactory, though it may not be as highly specific as capillary electrophoresis and 
high-performance ion chromatography. The incorporation of deproteinization step by 
membrane ultrafiltration in this assay removes effectively the protein and hemoglobin 
interference. The assay can be used for detection of hypocitraturia in patients with 
nephrolithiasis. The evaluation results are also similar to those published for the manual 
method[48]. 
The reagents used are inexpensive except for the membrane filters employed in 
the deproteinization step. Nevertheless, phenylhydrazine is poisonous and requires 
proper safety precaution. Its working solution is rather unstable since the dye 
decomposes in the aqueous solution within four hours. Working phenylhydrazine must 
be freshly prepared. Table 18 compares the analytical performance between the manual 
and Cobas Fara citrate lyase-phenylhydrazine methods for the urinary citrate assay. 
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Analytical Performance Manual method Cobas Fara method 
(Michele Petrarulo et al. 1995) (this project) 
Within-batch imprecision (a) 2.0 (at 0.96 mmol/L) (a) 3.0 (at 0.07 mmol/L) 
(% C.V.) (b) 1.0 (at 4.17 mmol/L) (b) 0.9 (at 0.70 mmol/L) 
(n= 10 for each level) (c ) 0.3 (at 4.36 mmol/L) 
(n= 20 for each level) 
Between-batch imprecision (a) 2.5 (at 0.96 mmol/L) (a) 5.9 (at 0.07 mmol/L) 
(% C.V.) (b) 1.4 (at 4.17 mmol/L) (b) l.l(at 0.70 mmol/L) 
(n= 10 for each level) (c)2.1 (at 4.36 mmol/L) 
- (n= 20 for each level) 
Mean recovery ± 1 SD (%) 
(spiked with 2.0 mmol/L citrate) 100.7 士 2.2 100.2 ±0.8 
Linearity range (mmol/L) 0 - 8 0 - 4 
Detection limit (mmol/L) 0.08 0.05 
(conc. at which C.V = 10%) 
Blank drift (mA/min) 0- 0.3 0.2 - 0.7 
Correlation coefficient (r) between 0.996 0.970 
this and traditional methods (n=65) (n=40) 
(y=L006x-0.022) (y=0.9561x +0.0921) 
Interference studies: no interference up to: no interference up to: 
1. pyruvate 2.0 mmol/L 2.0 mmol/L 
2. oxaloacetic acid 2.0 mmol/L 2.0 mmol/L 
(A= absorbance unit) 
Table 18 : Comparison of analytical performance between the manual and Cobas Fara 
citrate lyase-phenylhydrazine methods for quantitation of urinary citrate 
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8. Study in Control Subjects 
8.1 Subjects 
Forty-two Chinese healthy adults (twenty-four males and eighteen females) from 
the staff in the Chemical Pathology Laboratory of the Queen Elizabeth Hospital in 
Hong Kong or their relatives were recruited as the control subjects. They were free of 
overt diseases and had no previous history of nephrolithiasis or urinary tract diseases. 
No radiologic examination was conducted. Their ages ranged from 21 to 71 years (male: 
mean = 34 ； female: mean = 36). They were on free diet at the time of study. Twenty-
four hour urine was collected in a 3-litre plastic bottle with HC1 as preservative. The 
specimens were sent to the laboratory as soon as possible. Aliquots made after 
thorough mixing of the urine specimen were immediately stored at -40°C 
8.2 Method of Evaluation 
The specimens were checked for 24-hour volume, creatinine and urea excretion. 
Any samples with abnormal results were excluded. 
Urinary citrate was studied in context with other 24-hour urinary excretion of 
stone constituents i.e. calcium, oxalate and phosphate and of another stone inhibitor, 
magnesium. 
Creatinine, urea, calcium and phosphate were assayed by the BM/Hitachi 747 
analyzer (Boehringer-Mannheim Diagnostics). 
Magnesium was quantitated by the Kodak Ektachem 700 analyzer C series 
(Johnson and Johnson Diagnostics). Magnesium ion (Mg2+) in urine exists mainly as 
magnesium phosphate. About 5-ml aliquot of a 24-hour urine specimen was initially 
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adjusted to pH 3.0 - 4.0 with 5 M sodium hydroxide, in order to release Mg2+ from the 
phosphate. The acidified sample was 6-fold diluted to eliminate potential interference 
from the urinary phosphate. Mg2+ forms a colored complex with a formazan dye, 1,5-
bis(2-hydroxy-3,5-dichlorophenyl)-3-cyanofonnazan coated on the slide. The intensity 
of the color produced is directly proportional to the concentration of magnesium in the 
sample. Urinary Ca2+ is chelated with l’2-bis(o-aminophenoxy)-ethane-N，N，N'，N'-
tetraacetic acid and will not interfere with the assay. 
Oxalate was measured by the Sigma Diagnostics Oxalate Reagent kit (lot number: 
591-D) using the Cobas Mira analyzer (Roche Diagnostic Systems). A 2-ml aliquot of a 
24-hour urine sample was prediluted with the sample diluent, and adjusted to pH 6 
using 1M HC1 or 1M NaOH. The diluted sample was then purified by activated 
charcoal and centrifuged to obtain the supernatant for analysis. Oxalate in the 
supernatant is oxidized to carbon dioxide and hydrogen peroxide by oxalate oxidase. 
The hydrogen peroxide reacts with 3-methyl-2-benzothiazolinone hydrazone and 3-
[dimethylamino] benzoic acid in the presence of peroxidase to yield an indamine dye. 
This dye has an absorbance maximum at 590 nm. The absorbance change measured is 
directly proportional to the oxalate concentration in the sample. 
The skewness and kurtosis of the result distribution for each analyte were 
calculated on the male and female groups respectively, to see if the distribution is of 
Gaussian characteristics. The mean, standard deviation, 2.5th and 97.5th percentiles 
were analyzed by statistical package Excel version 7.0 for Window 95 (Microsoft 
Corporation, USA). The Student unpaired t-test and Mann-Whitney U test were used 
respectively to assess any sex differences in analytes exhibiting the Gaussian distribution 
and non-Gaussian distribution. The significance level was set at 0.05. 
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8.3 Results of the Control Subjects 
The results from the control subjects were summarized in the table 19. A 
significant difference in the 24-hour urinary citrate excretion was indicated between the 
Chinese male and female controls (p<0.05, t test). 
8.4 Discussion 
The results of 24-hour urinary citrate excretion in normal Chinese males and 
females indicate that females excrete more citrate than males. This sex difference has 
been generally observed in Western population[37,54,55]. It offers a potential 
explanation that women are less prone to nephrolithiasis because of higher urinary 
citrate excretion. 
Sex hormones are postulated to affect renal citrate excretion by undefined 
mechanisms. Some studies have demonstrated that urinary citrate excretion is higher 
during the latter half of the normal menstrual cycle than the first half by 0.5 to 1.0 mmol 
per day[56]. During pregnancy, urinary citrate increases by 2.6 to 5.2 mmol per day. 
Postmenopausal women excrete less citrate than premenopausal ones. These findings 
have been attributed to the action of estrogen or progesterone or both. It is believed 
that the two female sex hormones augment, whilst androgens reduce, the citrate 
excretion. However, other studies revealed no significant difference in the urinary 
citrate excretion between the two sexes, although the urinary citrate was generally 
higher in females[34,57,58]. 
Within the adult age range, there is no age-dependency found in the urinary citrate 
excretion in the Chinese male and female controls. There is no consensus in whether 
there is an age-dependent rise in the urinary citrate in Western population[37,59]. Some 
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„ 一 — ― 一 — u r i n e vol. Calcium Oxalate Phosphate Citrate MagnesiumCalcium:citrate 
(L/day) (mmol/day) (mmol/day) (mmol/day) (mmol/day) (mmol/day) 
I Mate Mean 1.9 5.5 0.36 27.7 1.83 3.6 3.7 
I (n=24) Distribution Gaussian non-Gaussian Gaussian Gaussian Gaussian Gaussian non-Gaussian 
(skewness.kurtosis) 0.3,2.0 1.4,4.5 (-0.3),3.7 (-0.1),4.2 0.02,3.1 0:4,1.9 1.5,4.9 
Range: 
Mean +/-2SD 0.6-3.4 - 0.13-0.59 12.4-43.1 0.33-3.32 0.5 - 6.7 -
2.5% to 97.5% - 2.8 -12.6 , - - 1.4-8.1 
Female Mean 1Q* 3.8® 0.27b 18.1C 2.62d 2.9* 1.8* 
(n=18) Distribution Gaussian non-Gaussian Gaussian Gaussian Gaussian Gaussian non-Gaussian 
(skewness.kurtosis) (-0.3), 2.9 1.1,3.4 0.6,4 0.6,2.5 0.5,2.36 0.2,2.4 1.3,3.1 
Range: 
Mean +/-2SD 0.7-3.1 - 0.14 _(U0 8.6 - 27.6 0.37 - 4.66 0.6 - 5.3 -
2.5% to 97.5% - 1.2-9.0 - - - - 0.7-4.7 
！ Combined mean 1.9 - - - 3.3 -
I Combined (mean +1- 2SD) 0.9 - 2.9 • - - - 0.5 - 6.1 
a Significant lower urinaiy calcium in female (p<0.05) 
b Significant lower urinary phosphate in female (p<0.001) 
c Significant lower urinary oxalate in female (p<0.001) 
d Significant higher urinaiy citrate in female (p<0.05) 
e Significant lower urinary calcium xitrate ratio in female (p<0.05) 
\ * No significant differences in urine volume (p>0.5) and magnesium (p>0.1) between both sexes 
Table 19 : 24-hour urinary excretion of calcium, oxalate, phosphate, citrate and 
magnesium in the Chinese male and female controls 
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researchers found that the daily excretion of citrate increased with age to a maximum 
during the fifth decade, and remained relatively constant until the eighth decade when it 
decreased[60]. Other studies revealed no such relationship[6,37]. 
Comparison of the reference ranges of urinary citrate between the Chinese and 
Western population is difficult, owing to wide variations in the ranges established by 
different laboratories[37,58,59,60]. The reference range may be affected by racial, 
genetic and dietary factors as well as the methodologic differences in the citrate assay. 
A comparison of the reference ranges in different races was shown in table 20. Citrate 
lyase methods were used for the citrate assay in all of the studies, the automated citrate 
lyase-phenylhydrazine method used in this project had been correlated with the 
traditional citrate lyase method used in the other studies. The different reference ranges 
of urinary citrate are probably attributed to other factors rather than the methodologic 
differences in the citrate assays. 
The reference range of 24-hour urinary citrate excretion in the Chinese male 
controls in Hong Kong matched with that of the Chinese normal males (age-matched: 
mean:35, range: 25 to 56) in Taiwan [ 6 ]. No comparison of the urinary citrate 
between the Chinese female controls in Hong Kong and in other geographic regions 
could be attempted owing to rare researches done. Nevertheless, the mean urinary 
citrate excretion in both sexes of the Chinese controls in Hong Kong and in the Chinese 
normal males in Taiwan were generally lower than those in Western population. Such 
variation may result from differences in the acid-base diet load (such as high animal 
protein intake) or in vitamin D intake between Chinese and Westerners[ 6 ]. Excessive 
animal protein intake and vitamin D deficiency are associated with reduced urinary 
citrate excretion[20]. Racial factor may contribute to the different reference ranges. 
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Urinary citrate excretion 
(mmol/day) 
Male Controls 
Country and age range (yr.) c n / � Female Controls 
mean, S.D. (n) 
mean，S.D. (n) 
USA a, 20 - 55 2.85，0.91 (32) 3.80, 1.25(27) 
South A f r i c a 2 6 - 6 3 3 ' 3 9 ' 1 1 3 3 5 2 ' 0 5 4 
Italy c , 21 - 40 2 . 2 4， 0 6 8 ( 3 9 ) 2 . 2 4 ' 0 7 0 ( 4 3 ) 
4 1 _ 6 0 2.34, 0.95 (29) 2.24, 0.87 (30) 
T . d oc 1.89,0.62(32) -Taiwan , 2 5 - 5 6 ， � , 
Hong Konge, 21 - 71 1.83, 0.75 (24) 2.52’ 1.07 (18) 
a Parks & Coe (1986) 
b Laminskiefa/.(1990) 
c Trinchieri efa/.(1992) 
d Chen ef a/. (1991) 
e this project 
Table 20 : Comparison of 24-hour urinary citrate excretion in control subjects in 
different studies 
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Chinese male controls produced no more urine than the female controls, yet they 
excreted significantly more calcium, oxalate and phosphate. Their urine was more 
concentrated with these constituents of renal stone, but contained a lower content of 
citrate. These findings are consistent with other studies in Western population[37,61], 
and provide evidence supporting the higher risk of males to develop nephrolithiasis than 
females. No remarkable difference was found in the urinary magnesium between the 
Chinese male and female controls. 
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9. Study in Chinese Patients with Nephrolithiasis 
9.1 Subjects 
Forty-eight Chinese renal-stone patients with no apparent cause (twenty-six males, 
twenty-two females), diagnosed by clinical and radiologic examination (x-rays, 
ultrasound or intravenous urogram) were selected from the Urologic Clinic of Queen 
Elizabeth Hospital in Hong Kong. Their ages ranged from 20 to 78 years (male: 
mean=50 ； female: mean=53). They were not on special diet or medication at the time 
of study. 
9.2 Method of the Patients Study 
The same procedures of sample collection, preservation, reception and storage and 
the same urine test profile were performed for the patients as for the controls. The 
Student unpaired t test and Mann-Whitney U test were used to evaluate any difference 
in the urinary excretion between the sex-matched stone former and control groups for 
analytes exhibiting the Gaussian and non-Gaussian distribution respectively. The 
significant level was set at 0.05. 
9.3 Results of the Patients Study 
The results from the Chinese patients with nephrolithiasis were summarized in the 
scatter plots (figures 9 to 11) and table 21. Compared to the sex-matched control 
groups, the Chinese male and female stone-formers excreted significantly less citrate 
(male: p<0.0001; female: p<0.02’ t test). 
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Figure 9 : 24-hour urinary citrate excretion in Chinese 
stone formers and controls 
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Figure 10 : 24-hour urinary magnesium excretion in 
Chinese stone formers and controls 
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Figure 11 : 24-hour urinary molar ratio of calcium to citrate in 
Chinese stone formers and controls 
7 5 
Urinary excretion Male stone patients Female stone patients 
mean range mean range 
• • . • . . . . . . . � 
calcium (mmol/day) " " 1.1-11.2 4^ °-4-9-1 
oxalate (mmol/day) 0.41 0.26-1.07 0.31 0.09-0.61 
phosphate (mmol/day) 25.2 10.8-57.0 19.90 6.1-35.4 
citrate (mmol/day) 1 00 0.15-2.06 1.49 0.08-6.03 
molar ratio of calcium to 6.5 0.8-21.4 7,1 1.1-23,4 
citrate 
volume (L/day) combined 1.9 combined 0.9 - 2.9 
mean range 
magnesium (mmol/day) combined 2.6 combined 0.5 - 5.7 
mean range 
* Chinese stone patients excreted significantly less citrate than the Chinese controls in both sexes 
(male: p<0.0001 ； female: p<0.02) 
No significant difference in the urinary citrate between the Chinese male and female stone formers 
(P>0.1) 
* Chinese stone patients excreted significantly lower magnesium than the Chinese controls (p<0.05) 
* Chinese stone patients had higher calcium: citrate ratio than the Chinese controls in both sexes 
(male :p<0.01 ； female :p<0.002) 
* No significant difference in the following between the stone patients and controls in both sexes: 
1. volume (p>0.6) 
2. calcium (male: p>0.4 ； female: p>0.3) 
3. oxalate (male: p>0.2 ； female: p>0.2) 
4. phosphate (male: p>0.3 ； female: p>0.3) 
Table 21 : 24-hour urinary excretion of calcium, oxalate, phosphate, citrate and 
magnesium in the Chinese patients with nephrolithiasis 
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9.4 Discussion 
The 24-hour urinary citrate excretion in the male and female patients with 
nephrolithiasis was significantly lower when compared to the sex-matched controls. 
This finding is consistent with the recognition in Western population that low urinary 
citrate excretion is prevalent in patients with nephrolithiasis[3]. The causes for the 
reduced urinary citrate excretion in the Chinese patients with nephrolithiasis need 
further investigation. 
Among the Chinese stone-formers, no significant difference in the urinary citrate 
was observed between men and women (p>0.1, t test). Similar results have been 
reported in Western patients with nephrolithiasis[37,57]. 
Apart from a decreased urinary citrate excretion, the Chinese stone-formers 
excreted significantly less magnesium than the Chinese controls (p<0.05, t test). Other 
studies on Western [60] and Chinese [ 6 ] stone formers had similar findings of the 
coexistence of hypocitraturia and hypomagnesiuria. Decreased urinary magnesium has 
been implicated as a cause of hypocitraturia. Magnesium forms a soluble complex with 
citrate in urine[62]. In the presence of reduced urinary magnesium excretion, a 
defective complex between these two ions may facilitate enhanced tubular uptake of 
free citrate ions and subsequent reduced urinary excretion[61]. Hypomagnesiuria as a 
cause of lower urinary citrate excretion in stone-formers could not be definitely 
excluded in the Chinese patients in this project. 
On the other hand, concerning the stone constituents, no remarkable differences 
in the calcium, oxalate and phosphate excretion were found in the patients with 
nephrolithiasis when compared to the sex-matched controls, though the urine of some 
patients contained much more lithogenic substances. Whilst there was no significant 
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increase in the lithogemc potential (excessive supersaturation) in the Chinese patients 
studied, the inhibitory strength against nephrolithiasis was distinguishably decreased in 
them, as exhibited by the coexistence of lower urinary citrate and magnesium excretion. 
A similar pattern of findings was indicated in the Chinese male stone-formers in 
Taiwan[ 6 ].The reduced inhibitor excretion plays an important role in the pathogenesis 
and recurrence of nephrolithiasis. 
In context with the theory of the balance between supersaturation and inhibition 
in the mechanism of nephrolithiasis, the molar ratio of urinary calcium to citrate in 24-
hour urine helps reflecting this dynamic state[37]. It determines the relative amount of 
free calcium available for complexing with urinary oxalate and phosphate to form renal 
stones. This ratio claimed by Parks and Coe is effective for discriminating the stone-
formers from healthy subjects, even where a significant reduction in the urinary citrate 
excretion is not demonstrable[37]. Parks and Coe have demonstrated the mean molar 
ratio of urinary calcium to citrate was remarkably elevated in the patients with 
nephrolithiasis when compared to the control subjects, and a greater increase was found 
in the female patients than in the male patients[37]. Similar findings were revealed by 
other researches on Western population[63], one Chinese study[ 6 ] and this project. A 
comparison of the results was summarized in table 22. The higher molar ratios of 
urinary calcium to citrate in our Chinese stone-formers and control subjects when 
compared to the USA population, are explained by the lower urinary citrate excretion 
in Chinese, rather than by urinary calcium since Chinese people do not excrete 
significantly more calcium than Westerners. 
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Country Urinaiy citrate (mmol/day) 
Male patients Male controls Female patients Female controls 
mean, SEM (n) mean, SEM (n) mean, SEM (n) mean, SEM (n) 
USA8 2.69，0.08 (235) 2.85, 0.16(32) 2.87，0.13 (95) 3.80, 0.24 (27) 
Taiwanb 0.80,0.10(35) 1.89,0.11 (32) 輪 -
Hong Kongc 1.00，0.10 (26) 1.83, 0.15 (24) 1.49, 0.33 (22) 2.52，0.25 (18) 
Table 22 (i) : urinary citrate 
Country Mean molar ratio of calcium to citrate 
Male patients Male controls Female patients Female controls 
U S A a 4^ 5 3J0 3^ 5 U — 
Taiwanb 5 0 2 4 _ " 
Hong Kongc ^ ^ 7二 1 8 
Table 22 (ii) : molar ratio of calcium to citrate 
a Parks & Coe (1986) 
b Chen e/fl/. (1991) 
c this project 
Table 22 (i) & (ii): Comparison of the results on urinary citrate among the studies by 
Parks and Coe, Chen et al. and this project 
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10. General Discussion and Suggestions for Further Studies 
Nephrolithiasis has a similar incidence rate in the population of the United States 
and the Chinese in Hong Kong[l，2]. It is a common disorder and the recurrence 
\sdthout treatment is high. An understanding of the mechanism of renal stone formation 
dds to improve the patient management, thereby reducing the recurrence, morbidity 
and health care costs associated with nephrolithiasis. 
Western researches have confirmed that nephrolithiasis is a complex physico-
chemical process, motivated by the imbalance between the supersaturation of the stone 
constituents and their inhibitors in urine [ 3 ]. Many Western studies have been focused 
on the identification and roles of various stone inhibitors. Urinary citrate has been 
recognized as an important inhibitor of nephrolithiasis in Western population[18]. It 
chelates with urinary calcium to reduce supersaturation, and inhibits directly the 
nucleation, growth and aggregation of stone crystals[39,40,41]. Western researchers 
have demonstrated the therapeutic use of oral citrate in reducing the occurrence and 
recurrence of nephrolithiasis effectively[ 7 ]. 
Simpson and other researchers discovered that urinary citrate excretion is 
predominantly determined by renal proximal tubular reabsorption[20]. The reabsorption 
is remarkably sensitive to a change in the systemic acid-base balance, which controls the 
rate of the intra-mitochondrial citrate metabolism in the proximal tubules. Systemic 
acidosis enhances citrate reabsorption, thus reducing citrate excretion. Apart from the 
cause due to acid-base disturbance, hypocitraturia can be idiopathic associated with 
high animal protein or sodium intake, or intestinal malabsorption of citrate[18]. 
Western researches have also revealed that hypocitraturia is a frequent biochemical 
disturbance leading to nephrolithiasis[ 3 ]. However, comprehensive study of urinary 
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citrate excretion in the Chinese population and stone-formers is rare. 
This project was launched to investigate whether urinary citrate excretion is 
significantly reduced in Hong Kong patients with nephrolithiasis. To date, citrate level 
is mainly measured by three methodologies: enzymatic spectrophotometry using citrate 
lyase[47，48]，high performance ion-chromatography (HPIC) [49] and capillary 
electrophoresis (CE) [50]. The first one is simple, whilst the latter two are more 
sensitive, highly specific, and facilitates simultaneous multianalysis of urinary anions 
such as oxalate, phosphate and glycosaminoglycans. Owing to the limitations that HPIC 
and CE instruments are unavailable in the working place, an in-house automated citrate 
lyase phenylhydrazine method for quantitation of urinaiy citrate was adapted in the 
Cobas Fara discrete analyzer. This method is more sensitive than the manual version 
developed by Petrarulo et al [48] and the traditional citrate lyase method developed by 
Moellering & Gruber [47]. It has a lower detection limit (0.05 mmol/L) than these two 
enzymatic methods. The running time is within 15 minutes. It is a satisfactory method 
for detecting hypocitraturia in routine hospital laboratory service. Although this 
automated method is well correlated with the traditional one, an external quality control 
program should be joined to monitor the assay performance. To date such a program is 
not yet available. 
Despite the limited numbers of the Chinese controls and stone-formers recruited 
in this project, the findings of daily citrate excretion in urine were similar with those in 
another Chinese population in Taiwan[ 6 ], as well as in Westerners[37]. These studies 
demonstrate that normal females excrete more citrate than males, and patients with 
nephrolithiasis excrete remarkably less citrate than normal sex-matched subjects in 
both sexes. In addition, the reference ranges of urinary citrate matches between the 
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Chinese male controls in Hong Kong and in Taiwan. These two Chinese population 
excrete less citrate than the Westerners living in USA, South Africans and Italians. 
Further comparison of the reference ranges of urinary citrate should be attempted 
among different Chinese population, as well as among Chinese and Western population. 
Any racial, genetic or dietary differences) contributing to the variations in urinary 
citrate excretion should be identified provided that the same methodologies of citrate 
assays are used. High animal protein diets favored by the Chinese in Hong Kong may 
predispose to low urinary citrate because of the acid load. 
In this project hypocitraturia was assigned as the urinary citrate excretion less 
than 0.65 mmol/day. This cut-off value was based on a similar study in Taiwan[ 6 ]. 
Different cut-off values for hypocitraturia in Western population have been established 
by different laboratories. For instance, Pak defined hypocitraturia as urinary citrate 
excretion less than 1.7 mmol/day[ 7 ]> This cut-off was based on the better clinical 
response of stone formers with urinary citrate below this level to citrate therapy than 
those excreted citrate more than 1.7 mmol/day. The cut-off value, 0.65 mmol/day, was 
selected since both the Taiwan and our studies are similar and showed similar results. 
Moreover, the estimated differences in the cut-off values for hypocitraturia between 
Chinese and Westerners (about 1 mmol/day) are approximately similar to their 
differences in the urinary citrate excretion. According to this cut-off value, 
hypocitraturia was found in about 33% (16/48) of our Chinese patients with 
nephrolithiasis. A similar incidence rate of hypocitraturia (around 45%) was found in 
the Chinese patients with nephrolithiasis in Taiwan[ 6 ]• Enhanced renal tubular 
reabsorption of citrate was demonstrated in the Taiwan stone-formers with 
hypocitraturia. A comparison of the incidence rates of hypocitraturia in stone formers 
a 
are shown in table 23. 
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Country % hypocitraturia in the stone patients 
% (cutoff value in mmol/day) 
USAa 15 - 63% (1.7) 
Taiwanb 45% (0.65) 
Hong Kongc 33% (0.65) 
a Balaji&Menon，1997 
b Chen etal 1991 
c this project 
Table 23 : A comparison of the incidence rates of hypocitraturia in stone formers 
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11. Conclusion 
In conclusion, hypocitraturia is a common predisposition factor in Chinese patients 
with nephrolithiasis. Oral citrate therapy should be considered to reduce recurrence of 
nephrolithiasis. The automated citrate-lyase phenylhydrazine assay for urinary citrate is 
useful to diagnose hypocitraturia and monitor these patients on citrate therapy. 
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